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1. LIST OF ABBREVIATIONS 
Ac alternating current  
ACN acetonitrile 
amu atomic mass unit 
APCI atmospheric pressure chemical ionization 
API atmospheric pressure ionization 
AUC area under the curve  
CID collision induced dissociation 
cmax peak concentration 
CNLS constant neutral-loss scanning 
CV coefficient of variation 
DAD diode array detection 
Dc direct current 
DDA data-dependent acquisition 
DIS daughter-ion scanning 
EMIT enzyme multiplied immunotechniques 
ESI electrospray ionization 
FAB fast atom bombardment 
GC gas chromatography 
GUS general unknown screening 
HPLC high performance liquid chromatography 
IS internal standard 
LC liquid chromatography 
LLE liquid-liquid extraction 
LOD limit of detection 
ME matrix effect 
MRM multiple-reaction monitoring 
MS mass spectrometry 
PB particle beam 
RF radio frequency 
RI retention index 
RP reversed-phase 
RT retention time 
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RRT relative retention time 
SIM selected-ion monitoring mode 
SPE solid phase extraction 
SRM selected-reaction monitoring 
STA systematic toxicological analysis 
t1/2 half-life 
TIC total ion current 
tmax time to peak concentration 
TS thermospray 
TOF time-of-flight 
UV ultra violet 
XIC extracted ion chromatogram 
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2. SUMMARY 
Screening for a wide range of drugs and toxic compounds in biological samples is an 
important task for forensic and clinical toxicological laboratories. Our object was to 
develop a method to detect and identify a wide range of compounds by using HPLC-
DAD and LC-MS. 
 
A solid-phase extraction procedure using polymer-based columns was developed for the 
HPLC-DAD procedure. The extraction method appeared very universal. Ninteyfour of 
100 drugs were extracted with a recovery of more than 50%.  
For the LC-MS procedure, the Prospekt solid-phase extraction was chosen for its ability 
to be linked to the atmospheric pressure chemical ionisation (APCI) ion source. With this 
procedure all of the tested drugs with LC-MS were successfully extracted. 
 
Hundred compounds from a variety of classes were investigated, if they can be identified 
and detected at low toxic serum concentration. Limits of detection were determined in 
spiked serum samples. 
 
It was found that HPLC-DAD was able to detect 61 out of 100 compounds with our 
procedure at low toxic serum concentration. The limit of detection (LOD) for the 
majority of the tested drugs (76%) was ≤ 1’000 ng/mL. Drugs and toxic compounds were 
detected by comparison of the retention time and UV spectra with references compounds 
stored in a library. 
 
The LC-MS instrument was operated in the positive and in the negative mode using data-
dependent acquisition. Tandem mass spectrometry (MS-MS) was applied to identify 
toxicologically relevant substances in serum. An application program was created in 
order to detect automatically the unknown compounds. Drugs and metabolites were 
identified on the basis of their relative retention times, pseudo-molecular ions and 
fragment ions. A total of more than 400 spectra of more than 350 compounds were 
recorded. The corresponding relative retention times were added to the spectra in the 
constructed libraries (one for the positive and the other library for the negative mode). 
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Eightyseven drugs of compounds were identified from serum using on-line solid-phase 
extraction with LC-MS-MS. The limit of detection (LOD) for the majority of compounds 
(67%) was ≤ 100 ng/mL, ranging from 10 to 4000 ng/mL. 
 
With the presented fully automated data-dependent LC-MS-MS procedure drugs can be 
analysed in serum with a high specificity and sensitivity. The LODs were sufficiently low 
to detect compounds at low toxic concentrations in serum. The integrated software 
drastically reduced the interpretation time. It was demonstrated that with the DDA-
mediated-LC-MS-MS screening approach almost all of the drugs detected by the 
conventional techniques as well as additional drugs were identified. This technique is 
useful for GUS and confirmation analysis in clinical and forensic toxicology. In general, 
LOD for compounds are lower with the LC-MS procedure than the HPLC procedure. For 
compounds not able to detect with the LC-MS procedure such as analgesics and 
barbiturates HPLC-DAD appeared to be the complement method. 
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3. INTRODUCTION 
3.1. GENERAL UNKNOWN SCREENING 
The identification of unknown compounds taken during an acute poisoning episode is a 
challenging task in clinical and forensic toxicology. The screening for drugs and toxic 
compounds is called general unknown screening (GUS) or systematic toxicological 
analysis (STA). This procedure is an analytical method aimed to detect and identify 
unknown xenobiotics in biological fluids. 
 
Acute poisoning with drugs is one of the most often occurring types of intoxication with 
exogenous compounds. In the year 2003, the number of intoxication incidents was 
about 24’000 in Switzerland. Drugs are the reason for two-thirds of the poisonings in 
Switzerland with an assured medical diagnosis. The poisonings can be voluntary 
(suicidal intention) in 22% or accidental (mostly children) in 72% of the cases 
according to the annual report of the Swiss Toxicological Centre. 
 
Following the usual course of STA, samples will initially be analysed by 
immunochemical techniques (enzyme multiplied immunotechniques (EMIT), 
fluorescence polarization immunoassays, etc) (1, 2). These preliminary 
immunochemical screening procedures mainly concern rapid-response analytical tools 
providing a binary yes/no response, which indicates whether the target analytes are 
present above a preset concentration threshold or not. The samples providing a „yes“ 
response to one or more compound classes or target substances are analysed with a 
conformation method. 
 
Apart from the first-line automated immunoassays available for the most common 
drugs, the GUS procedures currently used in clinical and forensic toxicology involve 
chromatographic techniques, ideally coupled to specific detectors (i.e., gas 
chromatography-mass spectrometry (GC-MS) (3) or high performance liquid 
chromatography (HPLC) coupled to diode array detection (DAD) (4-6)). 
 
None of these methods is sufficient to identify all possible toxic compounds. GC is 
limited to apolar, volatile and thermally stable compounds (7). For instance, some polar 
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compounds with no or little UV absorbency will neither be detected by GC-MS nor by 
HPLC-DAD. MS is more specific and reliable than DAD. The coupling of MS to HPLC 
seems to be a possibility to increase the range of compounds amenable to MS (8). 
3.2. CHOICE OF SPECIMEN 
The choice of specimen is often dictated by the clinical situation. The most common 
specimens used for the screening of drugs are blood, serum/plasma, and urine. Blood, 
plasma and serum are interchangeable in most methods. Urine is the most frequent 
specimen used in most hospital situations and may require hydrolysis prior to the 
isolation procedure to convert drug conjugates (glucuronides) to more easily measurable 
compounds. In forensic medicine the most investigated specimen is whole blood. 
3.3. EXTRACTION TECHNIQUES 
Chromatographic techniques require a preanalytical isolation procedure to separate 
drugs from a biological matrix. There are two main suitable procedures for a GUS: 
liquid-liquid extraction and solid-phase extraction. The extract can be concentrated and 
dissolved in an appropriate volume of mobile phase. 
 
In some cases filtration or precipitation of proteins with an organic solvent (such as 
acetonitrile) prior to injection can provide a more direct means to introduce a sample 
into a HPLC. But these extraction procedures are not sufficient for a GUS. 
3.3.1. Liquid-Liquid Extraction 
This has been the traditional method for isolating drugs from biological specimen. A 
distribution of the solute occurs between two not mixable liquids (specimen as the 
aqueous phase and a solvent as the organic phase). The isolation has to be performed 
at a pH at which the analyte is uncharged. For acidic drugs the aqueous phase has to 
be acidified, for basic drugs the aqueous phase has to be basified. In liquid-liquid 
extraction (LLE) ethyl acetate, acetone, chloroform, toluene, dichloromethane, butyl 
acetate and diethyl ether have been used as organic phases (9). The extraction power 
of these solvents differ not much from each other (10). 
 
Although LLE is still used today, there are a number of drawbacks that limit its 
usefulness. Liquid-liquid extractions are difficult to automate. So this extraction 
procedure is labour intensive and time consuming. It’s more difficult to reproduce the 
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resulting data than with SPE (11). Emulsion formation, increased solvent use and 
subsequent waste leading to environmental and safety issues are additional problems 
of LLE. These drawbacks have led to the development of other separation methods 
such as solid-phase extraction (SPE). 
3.3.2. Solid-Phase Extraction 
SPE on columns consists of four basic steps. Condition to wet and activate the column 
packing bed is the first step. Then the analytes of interest are loaded on the column to 
allow retention. In SPE, the analytes to be extracted are partioned between a solid and 
a liquid. They must have greater affinity for the solid phase than for the sample matrix. 
Ideally interfering compounds are rinsed off during the washing step and then the 
analytes are desorbed with a solvent appropriate for instrumental analysis. The 
principles of separation involve intermolecular forces between the analyte and the 
sorbent, the liquid phase or sample matrix. These intermolecular forces are dipole-
dipole forces, hydrogen bonding, ionic interactions and Van der Waal forces. 
 
The main sorbents in GUS used for solid phase extraction are reversed-phase and ion-
exchange. 
 
Reversed-phase (RP) chromatography partitions organic solutes from a polar phase 
(generally aqueous) to a non-polar phase, which may be in form of a hydrocarbon 
chain or polymeric sorbent. It involves non-polar interaction of the solute with the 
stationary phase through low-energy Van der Waals forces. The affinity of the solute 
for the sorbent depends upon its hydrophobicity. The solute is eluted with organic 
solvent, often acetonitrile, ethyl acetate or methanol. The most common RP sorbents 
for SPE are chemically bonded silica phases (12-14). Most widely used bonded phases 
are C18 and C8 sorbents (15). Pre-treatment is necessary with solvents such as 
acetonitrile or methanol. 
 
Other sorbents used for RP extractions include highly cross-linked co-polymers 
(styrene-divinylbenzene) (13, 16). Compared with silica sorbents, these sorbents are 
generally more hydrophobic, more retentive, stable over a larger pH range and do not 
have secondary (unbounded hydroxy silanol) groups. They can be used in automated 
on-line combined extraction and analysis systems. 
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Oasis HLB (Waters) combines hydrophilic N-vinylpyrrolidone and lipophilic 
divinylbenzene, providing a hydrophilic-lipophilic balance. That means these 
cartridges have a large range to interact with different substances. This sorbent 
requires no conditioning step. Drying out does not destroy the structure of the sorbent 
compared to others (13). 
 
In ion-exchange sorbents, compounds are extracted by a high-energy ionic interaction 
with the sorbent. Strong anion-exchangers retain anions by quarternary amines as 
exchange groups, cation-exchangers groups retain cations by sulfonic acids. For 
extraction, the pH of the samples is adjusted so that the solute molecules are ionized. 
They are absorbed at oppositely charged sites of the sorbent. Changing the pH elutes 
them. Mixed-mode sorbents have both non-polar and ion-exchange functional groups. 
The combination is chosen so that an analyte is retained by both mechanisms (15). 
 
The SPE mechanism is more selective than liquid-liquid extraction because it is based 
on interaction between sample components and the sorbent, as well as on solubility. 
The more selective retention mechanism of SPE has a number of advantages over 
liquid-liquid extractions such as cleaner extracts, increased selectivity for the 
compounds of interest, no emulsion formation, larger selection of solvents available 
for use, and smaller volumes of solvent may be used for extraction. In general SPE can 
be used for smaller sample sizes. SPE also is less time consuming, and the procedure 
can be automated. Because of the short analysis time, volatile compounds also may be 
analyzed without significant loss (17). 
 
The majority of methods have used silica-based columns. Although successful, silica-
based sorbents may have a number of drawbacks. First, for bonded phases, the 
reaction between the organosilane and the silica is incomplete, leaving unreacted 
silanol groups that can act as cation-exchange sites and creating a secondary retention 
mechanism. End-capping reduces the amount of free silanols by converting the 
hydroxyl group to a methoxy group but it is not 100% effective. Second, the sorbent is 
not stable at pH extremes. At pH below 2, there can be breakdown of the silyl ether 
linkage. 
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The polymer-based sorbents were developed to overcome the limitations of silica-
based sorbents. The water-wettable sorbent is promoted for its ability to retain a wide 
spectrum of polar and nonpolar compounds and to remain stable from pH 1 to 14 (13). 
 
The automation of solid-phase extraction has different benefits. Precision, recovery 
and accuracy with fewer operator errors, reduced analysis time are some of these 
advantages (12, 14). In addition the automated SPE system can be connected directly 
to an analyser. Disadvantages can be the risk of carry-over and the loss of sensitivity 
(18). 
3.4. CHROMATOGRAPHY 
An autosampler is used to inject samples automatically into the liquid chromatography 
(LC) system. The high performance liquid chromatograph separates a sample into its 
chemical components by liquid chromatography. In liquid chromatography, the sample 
mixture partions between a solid stationary phase (column) of large surface area and a 
liquid mobile phase that passes through the column. The chemical properties of the 
components, the column and the mobile phase determine when each component elutes 
from the LC and enters the DAD system or the MS. 
3.4.1. HPLC-DAD System 
Diode-array ultraviolet detectors record the absorbance of compounds over a range of 
wavelengths (e.g., 200-400 nm) as they pass through the detector flow cell, thus 
allowing the on-line acquisition of UV spectra. 
 
The HPLC-DAD system has been extensively shown to be an efficient and practical 
method for both clinical and forensic toxicological investigations. This system is able 
to screen for a wide range of compounds including benzodiazepines, analgesics, 
diuretics, tricyclic antidepressants, drugs of abuse (amphetamines, cocaine) and 
barbiturates. Elliott and Hale had shown a screening of basic, acidic, and neutral 
drugs, providing reproducible results (19). 
 
Using the diode-array facility, it is also possible to detect any probable metabolites, 
which are not available as drug standards by comparing UV spectrum of the proposed 
metabolite and the parent compound. Some phase-one metabolic transformations 
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(especially N-dealkylation and sometimes hydroxylation) do not alter the UV 
chromophore of a drug. The system and the retention index (RI) database should be 
combined with additional techniques such as liquid chromatography-mass 
spectrometry, thus providing a powerful identification tool that combines RI values, 
UV spectra, molecular masses and ion fragmentation spectra. 
3.4.2. LC-MS System 
The LC-MS system consists of an atmospheric pressure ionization (API) source, ion 
optics, mass analyzer, and ion detection system. Ionization of the sample takes place 
in the API source. The ions produced in the API source are transmitted by the ion 
optics into the mass analyser. Selected ions are ejected from the mass analyzer and 
reach the ion detection system where they produce a signal. Fig. 1 shows a schematic 
drawing of a liquid-chromatography mass spectrometer system. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic drawing of a liquid-chromatography mass spectrometer. 
 
3.4.2.1. Interfaces 
LC-MS interfaces remove the mobile phase and ionize the analyte. Different LC-MS 
interface types such as moving belt, direct liquid introduction, continuous-flow or 
frit-terminated fast atom bombardment (FAB), particle beam (PB), thermospray 
(TS), electrospray (ESI) and atmospheric pressure chemical ionization (APCI) were 
developed. PB, FAB or TS have several limitations such as less sensitivity or less 
universality. Today, two relatively robust LC-MS interfaces types seem to have 
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become the golden standards of LC-MS, the atmospheric pressure ionization 
techniques, ESI and APCI. 
 
ESI and APCI have been used for a large majority of the applications of LC-MS in 
the last years. ESI and APCI involve a soft ionization process, which can be 
overcome by using collision-induced dissociation, which provides thorough 
fragmentation of the compounds. 
3.4.2.2. Electrospray Ionization 
The ESI mode transfers ions in solution into the gas phase. Many samples, which 
were previously not suitable for mass analysis (for example, heat-labile compounds 
or high molecular weight compounds) can be analyzed by ESI. ESI typically 
produces mass spectra consisting of multiply charged ions depending on the structure 
of the analyte and the solvent. 
 
ESI can be used to analyze any polar compound that generates an ion in solution. 
Generated ions include adduct ions (for example, polyethylene glycols can be 
analyzed from a solution containing ammonium acetate, because of the adduct 
formation between the NH4+ ions in solution and oxygen atoms in the polymer). 
With ESI the range of molecular weights that can be analyzed is greater than 100'000 
atomic mass units (amu), due to multiple charging. So proteins as well as peptides 
can be analyzed. 
 
The flow rate from the LC into the MS detector can vary over a range of 1 µL/min to 
1000 µL/min. Transported by the mobile phase the sample enters the ESI needle. To 
the needle a high voltage (+/- 5 kV) is applied. The needle with the aid of nitrogen 
gas sprays the sample solution into fine mist droplets. These droplets are electrically 
charged at their surface. Solvent evaporates from the droplets. The electrical charge 
density increases up to a critical point known as the Raylight stability limit. At this 
point, the droplets divide into smaller droplets (20, 21). This is because the 
electrostatic repulsion is greater than the surface tension. The process is repeated 
many times. Finally, sample ions are ejected from the cluster ions into the gas phase. 
This takes place in a heated capillary. 
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The ESI process is affected by droplet size, surface charge, liquid surface tension, 
solvent volatility, and ion solvation strength. Large droplets with high surface 
tension, low volatility, strong ion solvation, low surface charge, and high 
conductivity prevent a good electrospray process (20). 
3.4.2.3. Atmospheric Pressure Chemical Ionization 
Like ESI, APCI is a soft ionization technique. APCI provides molecular weight 
information for compounds of medium polarity that has some volatility. APCI is 
typically used to analyze molecules with molecular weight up to 2’000 amu. 
APCI is a gas phase ionization technique. Therefore, the pH of the analyte in the gas 
phase and solvent vapour play an important role in the APCI process. APCI is a very 
robust ionization technique. It is less affected by minor changes in most variables 
such as changes in buffer and buffer strength. The rate of solvent flowing from LC 
into the MS detector in APCI mode is typically high (between 0.2 and 2 mL/min) 
(22). 
 
The APCI nozzle vaporizes the sample solution in a high temperature tube. The 
needle is located near the end of the tube. A high voltage is applied to the corona 
discharge needle. Reagent ions are formed through a series of chemical reactions. 
First primary ions are formed. These primary ions can be nitrogen, oxygen gas or 
solvent molecules. The primary ions react with the molecules in the sample to form 
ions (21). 
 
APCI as well as ESI can be used in positive or negative ion polarity mode. A 
positive applied voltage is used to generate positive ions and a negative applied 
voltage to generate negatives. For most molecules, the ion-positive mode produces a 
stronger ion current. This is especially true for molecules with one or more basic 
nitrogen (or other basic) atoms. Molecules, which generally produce strong negative 
ions, with acidic sites such as carboxylic acids and acidic alcohols, are an exception 
to this general rule. Although, in general, fewer negative ions are produced than 
positive ions, negative ion polarity can be more specific. This is because the negative 
ion polarity mode sometimes generates less chemical noise than does the positive 
mode. Thus, selectivity might be better in the negative ion mode than in the positive 
ion mode. 
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3.4.2.4. Ion Transfer Capillary and Ion Optics 
The ion transfer capillary assists in desolvating ions that are produced by ESI and 
APCI probes. Ions are focussed into the ion transfer capillary in the atmospheric 
pressure region and transported to the skimmer region by decreasing pressure 
gradient and electrostatic forces. The ion transfer capillary can be heated. Typical 
temperatures are 150 to 200° C. Ions from the ion transfer capillary enter the tube 
lens. The tube lens has a dependent potential to focus the ions towards the skimmer. 
If the tube lens offset voltage is high, collisions with the background gas can be 
energetic enough to cause fragmentation. This fragmentation is called the ion source 
collision induced dissociation. The skimmer acts to reduce the number of neutral 
molecules and large charged particles. These particles would create detector noise. 
 
Ion optics (in our apparatus octapoles) transmits ions from the API source to the 
mass analyzer. Magnetic fields are used to direct and focus the ion stream coming 
from the source. 
3.4.2.5. Analysators and LC-MS Detection Modes 
Mass analysis of ionized substances is performed using one or two mass analyzers 
(MS-MS), which consist predominantly of ion traps and quadrupoles, sometimes of 
sector field and time-of-flight instruments (TOF). 
 
They can operate in the full scan mode or in the more sensitive selected-ion 
monitoring mode (SIM) detecting positive or negative ions. The MS-MS 
combination provides additional possibilities. Both analysers can be operated in a 
scan or in a selected-ion monitoring mode. 
 
The four combinations are: Parent-ion scanning (scan mode in the first, SIM in the 
second analyzer), daughter-ion scanning (DIS; SIM in the first, scan mode in the 
second analyzer), constant neutral-loss scanning (CNLS; scan mode in both 
analyzers) or selected-reaction monitoring (SRM; SIM in both analyzers). DIS is 
preferable for the identification of drugs and or their metabolites in complex 
matrices. Separation is performed on the LC and in the first mass analyzer, while 
structural information is obtained by fragmentation
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(also named multiple-reaction monitoring MRM) is the most powerful technique for 
quantification of small amounts of analyte in complex matrices (23, 24). 
 
Quadrupole is a quadrilateral array of square rods that acts as an ion transmission 
device. A radio-frequency voltage and direct current (dc) offset voltage, that are 
applied to the rods give rise to an electric field that guides the desired ions along the 
axis of the quadrupole. The other ions collides with the four square rods. During ion 
transmission, the offset voltage is negative for positive ions and positive for negative 
ions. Quadrupoles can also be placed in tandem to perform fragmentaion. 
Fragmentation takes place between the two quadrupoles in the collision cell. The 
most common set-up is the triple quadrupole mass spectrometer. 
 
The ion trap includes three electrodes: the entrance endcap electrode, the exit endcap 
electrode and the ring electrode. Both endcap electrodes have a small hole in their 
centre to permit the passage of ions into and out of the mass analyzer cavity. Various 
alternating current (ac) voltages are applied to the ring and endcap electrodes to trap, 
fragment, and eject ions according to their mass-to-charge ratios. 
 
The processes that occur in the mass analyzer can be divided in four steps: ion 
storage, ion isolation (SIM, SRM, and MS/MS full scan), collision induced 
dissociation (SRM and MS/MS full scan), and ion scan out. 
 
The application of a radio-frequency voltage to the ring electrode produces a three-
dimensional quadrupole field within the mass analyzer cavity. This time-varying 
field drives ionic motion in both the axial (towards the endcaps) and radial (from the 
ring electrode toward the centre) directions. Ionic motion must be stable in both the 
axial and radial directions for an ion to remain trapped. During ion scan out, the 
system produces a mass-dependent instability to eject ions from the mass analyzer in 
the axial direction. The voltage at which an ion is ejected from the mass analyzer is 
called its resonance voltage. 
 
Ac voltages that are applied to the endcap electrodes stimulate motion of the ions in 
the axial direction. The voltages applied to the endcap electrodes are equal in 
amplitude but are 180° out of phase to one another. When the radio-frequency 
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applied to the endcaps equals the resonance frequency of a trapped ion, the ion gains 
kinetic energy and the ion is ejected. 
 
During the collision induced dissociation a voltage is applied to the endcap 
electrodes to fragment ions into product ions. This voltage is not strong enough to 
eject an ion from the mass analyzer. However, ion motion in the axial direction is 
enhanced and the ion gains kinetic energy. The mass analyzer cavity contains helium 
as a collision activation partner. After many collisions with helium gas, the ion gains 
enough internal energy to cause it to dissociate into product ions. 
3.4.2.6. Data-Dependent Acquisition (DDA) 
In the first step (so-called "survey scan") the MS-MS instrument is operated in the 
full-scan single-mass mode using the second mass filter in order to select ions above 
a predefined intensity threshold. Instantly, the first mass filter is set to selectively 
transmit these high-intensity ions to the collision cell where fragmentation energy is 
switched on and the resulting fragments are analysed by the second mass filter in the 
scan mode. Finally after a short time the instrument switches back to the initial 
conditions, with the possibility to set a refractory period for the last ions selected. 
The major advantage of this approach is its high specificity and selectivity, as the 
spectra recorded come from a single parent ion. 
 
It can be difficult to detect toxic compounds among background noise. The setting of 
a given threshold can be important due to the intense and highly variable background 
noise produced by extracts of real samples. If the threshold is given a high value it 
results in very poor sensitivity but high specificity, and if it is given a very low value 
it may result in too much "noisy" information. 
3.4.2.7. Ion Detection System 
The ion detection system includes a 15 kV conversion dynode and a channel electron 
multiplier. A potential of + 15 kV for negative ion detection or – 15 kV for positive 
ion detection is applied to the conversion dynode. When an ion strikes the surface of 
the conversion dynode, one or more secondary particles are produced. These 
secondary particles can include positive, negative ions, electrons, and neutrals. When 
positive ions strike a negatively charged conversion dynode, the secondary particles 
of interest are negative ions and electrons. When negative ions strike a positively 
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charged conversion dynode, the secondary particles of interest are positive ions. 
These secondary particles are focused by the curved surface of the conversion 
dynode and are accelerated by a voltage gradient into the electron multiplier. 
Secondary particles from the conversion dynode strike the inner walls of the electron 
multiplier with sufficient energy to eject electrons. The ejected electrons are 
accelerated farther into the cathode, drawn by the increasingly positive gradient. Due 
to the funnel shape electrons do not travel far. They strike again the surface, thereby 
causing the emisson of more electrons. Thus, a cascade of electrons is created that 
finally results in a measurable current. The current is proportional to the number of 
secondary particles striking the cathode. 
3.4.2.8. Vacuum System 
Vacuum is necessary to perform and maintain a mass spectra analysis. At normal 
pressure the produced ions would collide with molecules (N2, O2, etc.) passing from 
the API stack to the ion detection system. High vacuum levels cause reduced 
sensitivity, and reduced lifetime of the electron multiplier. The vacuum system 
evacuates the region around the API stack, ion optics, mass analyzer, and ion 
detection system. A forepump establishes the vacuum necessary for the proper 
operation of the turbomolecular pump. The pump maintains a pressure of 
approximatively 1.33 mbar. A turbomolecular pump provides the vacuum for the ion 
optics and analyzer regions. Under normal operating conditions the vacuum in the 
API region is 1020 mbar and 2.67x10-5 mbar in the analyzer region. 
3.4.2.9. Adduct Formation 
Besides matrix effects, adduct formation also adds to the complexity of LC-MS. 
Generally, ESI or APCI result in deprotonated (M-H)- molecules in the negative 
mode and in protonated (M+H)+ molecules in the positive ionization mode. Several 
adduct ions such as (M+Na)+, (M+K)+, or (M+NH4)+ were also reported (25, 26). 
The exact mechanism in adduct formation is not clearly understood, carboxyl or 
carbonyl ether or ester groups are believed to be responsible for binding the alkali 
metal ions. Adduct formation process is not reproducible and consequently it is not 
clear, what adduct ion can be used for MRM. Addition of ammonium results in 
(M+NH4)+. The first step in fragmentation is the loss of neutral NH3. The latter can 
then fragment further. Sodium adduct ions are much more stable and yield less 
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fragments. It is clear that the evaluation of both matrix effects as well as adduct 
formation should be included in the validation procedure of a LC-MS method. 
3.4.3. Retention Time 
It is unusual for a substance to have an absolute retention time that remains constant 
either over a period of time (because of a gradual change of stationary phase) or 
between different batches of columns with nominally identical packing material. In 
order to account for this variability, relative retention time or retention index (RI) can 
be used as a method of correction. They are based on the relationship between a 
substance’s retention time and those of a reference compound. The use of retention 
index was shown to be advantageous (27). 
3.4.4. Chromatographic Conditions 
Drug screening is a qualitative technique for the identification of the presence of 
drugs. Gradient chromatography is needed for the analysis of the large diversity of 
substances. For quantitative LC analyses of compounds identified by screening, it can 
be more efficient to use isocratic chromatography. 
3.4.5. Influences of Biological Matrix 
3.4.5.1. Influences of Biological Matrix on Chromatographic Behaviour 
Bogusz et al. showed that the co-extracted biological matrix did not exert any 
specific influence on the chromatographic behaviour (28). The biological matrix did 
not affect the chromatography of acidic, neutral and basic drugs analyzed by means 
of gradient HPLC. To identify drugs extracted from biological samples, it is possible 
to use the retention time of pure drugs. 
3.4.5.2. Influences of Biological Matrix on Detection in HPLC 
The presence of extracted matrix substances can affect the identification of drugs by 
HPLC with a diode array detector spectrum library. These compounds can co-elute at 
the same time as some toxicologically relevant substances and overlap the 
corresponding UV spectra. The purity of the biological extract is therefore of critical 
importance for successful HPLC-DAD identification. 
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3.4.5.3. Influences of Biological Matrix on Detection in MS 
Matrix effect (ME) in mass spectrometry can be defined as any change in the 
ionization process of an analyte due to a co-eluting compound (29). This can result 
either in an enhancement or in a suppression of the ionization. Ion suppression or 
enhancement affects the precision, sensitivity and accuracy of an analytical 
procedure (30). 
 
Sample matrix, co-eluting compounds, and cross-talk can contribute to ion 
suppression. ESI is more impacted to ion suppression than APCI (31). 
 
In electrospray ionization (ESI) the ionization process is taking place in the liquid 
phase. Matrix effects in ESI are due to a competition of matrix compounds and 
molecules of interest for access to the droplet surface and subsequent gas-phase 
emission. Besides that, matrix constituents can change properties of the surface 
tension and viscosity. These factors are known to affect the ionization process (29). 
 
In APCI, the ionization is taking place in the gas phase. The non-volatile matrix 
compounds are thought to co-precipate with the analyte molecule. This influences 
the ionization process (32). 
 
In summary, ion suppression results form the presence of less volatile compounds 
that can change the efficiency of droplet formation or droplet evaporation, which in 
turn affects the amount of charged ion in the gas phase that reaches the detector. 
3.4.5.4. Evaluation of Matrix Effects in MS 
Matuszewski et al. described a procedure for the evaluation of matrix effects (33). 
Three sets of samples are necessary. Set A consists of neat standard solutions. For 
Set B blank matrices are supplemented (after extraction) with the same amount of 
standards as used for set A. Set C consists of extracts of different blank matrices, 
supplemented with the same amount of standards but added before extraction. Matrix 
effects (ME%), recovery (RE%) and process efficiency (PE%) can be calculated 
with different formula. For the calculation the resulting peak areas are needed. 
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ME% = B/A x 100 
RE% = C/B x 100 
PE% = C/A x 100 
 
Bonfiglio et al. described another procedure to evaluate matrix effects (34). This 
procedure is based on the postcolumn infusion of an analyte in a chromatographic 
run of an extract or a blank matrix. This signal is compared to the signal obtained 
with the post-column infusion of this same model analyte in a chromatographic run 
with eluent only. This procedure indicates also critical areas in the chromatogram. 
Typical examples of substances known to influence the ionization process include 
salts and other endogenous compounds (fatty acids, triglycerides), dosing vehicles 
(polyethylenglycol, propylenglycol and cremophore), anticoagulants, and 
constituents of sampling material (e.g. polymers) (35, 36). 
 
It was also demonstrated, that the ionization efficiency of a co-eluting internal 
standard (IS) is influenced by high levels of the compound of interest. 
 
Sample preparation also influences the amount of ion suppression. Protein 
precipitation alone results in pronounced matrix effects over the whole 
chromatographic run. SPE was able to remove efficiently hydrophilic interfering 
compounds. But hydrophobic interferences were increased. 
 
There are a few strategies to eliminate matrix effects, but often it is very difficult. A 
reduction of matrix constituents injected can help. This can be done by injecting a 
smaller sample volume, a diluted sample or by applying more selective extraction 
techniques. Then, co-elution of the analyte and matrix constituents should be 
avoided. But the separation on the liquid chromatographic system is limited. 
 
The use of co-eluting internal standard(s) such as labelled ISs seems ideal because it 
is expected that the matrix effect on the analyte and on the IS is identical. But 
labelled internal standards are not always available and costs are often very 
expensive. In addition, these standards cannot be used in a GUS. 
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The mobile phase influences the ionization efficiency in LC-MS. Additives can also 
have effects on matrix induced ion suppression or enhancement of an analyte. The 
addition of small amounts of ammonium formate resulted in better ME% values. 
Higher levels or to high levels of other acids suppressed the signal (37). 
3.5. MASS SPECTRA LIBRARIES 
Gas chromatography-mass spectrometry was applied for GUS over the last decades. It 
was shown that GC-MS is very specific, sensitive and is able to build very large 
libraries of standardized spectra (3). A successful GC-MS procedure requires a volatile, 
thermally stable analyte. But GC-MS fails often to detect polar and thermally labile and 
non-volatile compounds. These requirements generally necessitate extraction from the 
biological matrix, followed in many cases by derivatization. These limitations led to 
investigate other possibilities for analyzing biological specimens (HPLC-DAD, LC-MS 
(-MS)). 
3.5.1. Single Mass Spectrometry 
A proposed alternative for a GUS is single MS spectra. The mass spectrometer works 
in the scan mode and applies in-source CID. The sample is screened at variable orifice 
voltages. The peaks exceeding a preset intensity are identified by comparison of their 
spectra with in-source CID spectrum libraries. The spectra obtained using in source-
CID are mostly identically as those produced by conventional CID in the collision cell 
of a triple quadrupole mass spectrometry or of an ion trap. 
 
Marquet et al. described a procedure using full-scan from 100 to 1’100 amu, with a 
step of 0.2 amu (38). In source CID was set at four continuously alternated voltages. 
In the positive mode CID was with low energy 20 eV, in high CID with high energy 
80 eV, in the negative mode with low –20 eV, with high CID energy –80 eV. Several 
teams showed that fragmentation ensured reproducible in source CID spectra, at least 
using the same type of instruments (39). 
 
To obtain informative spectra (fragment ions and protonated molecule respectively 
molecular ion) pairs of full mass spectra were reconstructed by adding spectra at 20 
eV and 80 eV on one hand and –20 eV and – 80 eV on the other. These spectra were 
compared with spectra in the library. One library was built in the positive mode 
Introduction 
25 
containing 1’100 reconstructed mass spectra; the other library was built in the negative 
mode containing 500 reconstructed spectra. Software was developed in co-operation 
with the manufacturer to automatically reconstruct such spectra and compare each 
positive and negative spectrum, together with their relative retention time to those in 
the library. 
 
This LC-ES-MS technique was compared to GC-MS and HPLC-DAD GUS 
procedures for the identification of unknown compounds. 75% of the spiked 
compounds in these samples were identified by this method versus 66% for GC-MS 
and 71% for HPLC-DAD. The conclusion was that it was complementary to GC-MS 
and HPLC-DAD and helped enlarge the range of drugs detected (40). 
 
Gergov et al. also built such a library of reconstructed CID-MS spectra using a triple-
quadrupole mass spectrometry. They obtained the reconstructed spectra by the 
addition of spectra recorded at 25 eV and 90 eV (39). The authors concluded that the 
later mentioned MS/MS library showed better results. MS/MS spectra showed no 
interference caused by either co-elution of β-blocking drugs or matrix material as a 
result of its superior selectivity compared with single MS-CID. Better match indices 
were obtained. 
 
Weinmann et al. built a spectra library of 400 drugs using a triple quadrupole mass 
spectrometry (41). In source CID was applied at 20, 50, and 80 V only in the positive 
mode. No reconstructed spectra were obtained. Each spectrum obtained was compared 
to the library. This procedure cannot be called GUS because selective extraction 
procedures were applied and when interfering compounds or background noise 
occurred, they used MS/MS fragmentation. 
 
In summary, in-source CID mass spectra showed that they were reproducible with the 
same type of instruments (42). The main drawback of these techniques is the low 
specificity and selectivity, as the spectra recorded do not result from a single parent 
ion. To obtain good mass spectra of signals against a high background is almost 
impossible. This technique requires a completely separation of drugs and matrix 
compounds, which is not achievable. 
 
Introduction 
26 
Reports give hints of poor interinstrument reproducibility, which would require the 
development of mass spectral libraries for each brand. A standardization of the crucial 
parts of the instruments with respect to in-source CID would be necessary. This is one 
explanation of the absence of any large, commercial in-source CID mass spectral 
library so far (43). 
3.5.2. Tandem Mass Spectrometry 
Weinmann et al. built an MS-MS library of more than 500 therapeutic or illicit drugs 
using LC-ES-triple-quadrupole spectrometry (41). One or a few parent ions were 
selected in the first quadrupole (generally the protonated molecules in the positive 
ionization mode or the molecular ions in the negative mode). These ions were 
fragmented in the collision cell. The fragments were analyzed in the third quadrupole 
in the scan mode. Four different collision energies (20, 30, 40, 50 eV) were applied 
resulting in four different positive product-ion spectra. These spectra were recorded in 
the library for each compound. 
 
Gergov et al. developed a library of MS-MS spectra for almost 400 therapeutic or 
illicit drugs (39). Generally collision energy of 35 eV was applied to obtain MS-MS 
spectra. Additional spectra were acquired at 20 or 50 eV for those compounds giving 
no informative spectrum at 35 eV. In the first step of the operation, samples were pre-
screened using LC-MS-SIM. Any matches to a previously defined list of retention 
times and [M+H]+ were recorded. From this match a multi-period LC-MS-MS-CID 
product ion method was automatically created, that means these ions were selected as 
parent ions for product-ion scanning and library searching. This is a rather 
complicated process for a β-blocking screening, when direct product ion-scanning 
could have been applied. This method described a preliminary version of a data-
dependent acquisition. 
 
The same authors found a high reproducability of MS-MS CID-spectra between the 
instruments (44). They were using three different triple quadrupole instruments from 
the same manufacturer. Their results suggested good interinstrument fragmentation 
reproducability. 
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Baumann et al built a MS-MS library of more than 500 spectra using an ion-trap mass 
spectrometer in the positive mode (45). To obtain rich product ion spectra, resonance 
excitation at 20 amu below the parent ion selected was used, to further dissociate the 
[M+H-H2O]+ ions. A mass dependent correction was automatically applied to the 
collision energy, because generally fragmentation energy decreases linearly when 
mass increases. Specific MS-MS spectra of different substances could be recorded. 
 
The described libraries and methods are theoretically interesting but of little use in 
clinical toxicology. These procedures cannot be used as GUS methods, because 
samples are monitored only for a previously selected limited number of compounds. A 
solution to this limitation could be data-dependent acquisition. 
3.5.3. Data Dependent Acquisition 
 
The data dependent acquisition method was first used in a preliminary GUS procedure 
by Decaestecker et al (46). They used a time-of-flight detector in the positive 
electrospray mode. The quadrupole initially transmitted all masses (50 to 450). If an 
ion reached a predefined threshold the quadrupole selectively transmitted these high-
intensity ions to the collision cell operating with single fragmentation energy. The 
resulting fragments were analyzed in the TOF detector. The instrument switched back 
to the initial conditions. A refractory period was applied to the last selected ions for 2 
minutes. 
 
Fitzgerald et al used also the technique of data-dependent acquisition (47). They 
modified the commercially available column-switching instrument, the REMEDi HS 
from BioRad Diagnostics, to make it compatible with atmospheric pressure ionization. 
Urine samples were injected directly on the column switching system. The compounds 
were analyzed in the full scan mode between 50 and 500 amu. When any ion exceeded 
a preset threshold, they were selected and fragmented by collision-induced 
dissociation in the ion trap. 
 
The major advantage of these techniques is their high specificity and selectivity, as the 
spectra recorded come from a single parent ion. The main limitations of these works 
are that they do not explain the procedure to detect unknown substances. Also they did 
not mention the LOD of any substances. 
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In a further paper Decaestecker specified the different LOD of some drugs but still did 
not explain the mechanism of drug finding. They described that setting a low 
switching intensity threshold will increase the number of interferences detected. As a 
consequence, the interpretation of the data set was much more complicated. And no 
automated data interpretation was described. 
 
Marquet et al described a preliminary procedure for the screening of drugs using a 
quadrupole-linear ion-trap mass spectrometer (48). For the first detection step (so 
called „survey scan“) an „enhanced“ MS mode was used. Ions were accumulated and 
then filtered in the Q3-linear ion-trap. MS-MS mode for on-the-fly fragmentation of 
the ions above the user-defined data-dependent acquisition was applied. Four in-
source collision-induced fragmentation conditions are altered, low and high 
fragmentation in the positive and negative modes (20, 50, -15 and –40 V, 
respectively). Positive and negative reconstructed spectra were obtained by adding two 
spectra on the other. Better signal-to noise ratio was obtained with this method 
compared to the in source CID-MS technique of the same group; because the 
reconstructed mass spectra decreased the influence of contaminant ions. 
3.5.4. Sample Preparation in a General Unknown Screening 
Sample preparation is a key step in a screening procedure because the analytical 
system can not detect a compound if it is not extracted and so not injected in the 
system. The ideal extraction procedure would isolate the compounds of interest and 
eliminate the biological matrix compounds. The critical point is the signal-to-
background noise ratio. The signal-to-background noise is determined by the height of 
the chromatographic peaks and the baseline (purity of the extracts). 
 
Decaestecker et al tested an entire series of SPE sorbents for a LC-MS-MS general 
unknown screening (49). The sorbents were divided in three categories: apolar, mixed-
mode and polymeric. The extraction procedure was formulated individual for each 
column. Only neutral and basic compounds were chosen. 
From the apolar sorbents (Isolute C2, C4, C8, C18, C18 MF, PH and CN) the C8 packing 
material demonstrated the best overall extraction yield. MCX gave the best extraction 
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yields from the type from the mixed-mode category (MCX, HCX, HCX3, HCX5) and 
was slightly better than HLB from the polymeric category. 
 
Maurer et al proposed two extraction procedures for a GUS one with LLE and the 
other with SPE (50-52). In the LLE procedure method the sample was extracted at pH 
7 and at pH 12 with a mixture of diethyl ether/ethyl acetate (1:1, v/v). The organic 
phases were evaporated to dryness. The combined residues were dissolved in organic 
solution. 
In the SPE method samples were worked up with HCX columns. The compounds of 
interest were eluted with methanol/aqueous ammonia (98:2, v/v). A drawback of this 
extraction procedure is that the methods are not suitable for all drugs. For example 
benzodiazepines could not be extracted in a sufficient way with the SPE procedure. 
 
Venisse et al applied different extraction techniques using Extrelut, Oasis HLB and 
MCX cartridges. Both types of Oasis columns resulted in higher background noise, 
but the extraction and detection of tested compounds was much better than with 
Extrelut columns (53). 
 
In summary, only liquid-liquid extraction and solid phase extraction method were 
used. Liquid-liquid extraction requires two procedures, one for acidic and one for 
basic drugs. SPE was performed with mixed-mode cartridges, classic hydrophobic 
bonded phase or a polymer. 
3.5.5. Chromatic Conditions in a General Unknown Screening 
Most commonly used stationary phases were reversed-phase C18 columns. A short 
guard column with the same type of stationary phase is recommended. In LC-MS the 
mobile phases consisted of mixtures of volatile buffers (e.g. ammonium acetate or 
formate) with acidic pH and organic modifiers such as methanol and acetonitrile. In 
HPLC-DAD the mobile phase consisted of phosphate buffer with acidic pH and 
acetonitrile or methanol. Gradient elution was performed. 
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3.6. RESEARCH OBJECTIVE 
Acute poisonings account for 10 to 30% of the admissions to non-specialized care units, 
and 7 to 15% of autopsies performed in forensic institutions (4). Often, an intoxicated 
patient entering the hospital is consciousness or the patient or his relatives give 
misleading information. Consequently, the development of a reliable technique for 
general-unknown screening of pharmaceutical, toxicants and drugs of abuse in 
biological fluids is necessary. Such screening methods should be simple, rapid, 
reproducible, and available to cover a broad spectrum of toxicologically relevant 
substances, in one analytical run, with sufficient specifity. The combinations of mass 
spectrometry with suitable chromatographic procedures are the methods of choice, 
because they are very sensitive, precise, specific, universal and if coupled to automated 
extraction system very fast. 
It is necessary to speed up the process of a STA. The results should be given 
automatically. The aim of the project was to develop a fully-automated LC-MS method 
in combination with a HPLC-DAD method to detect a wide range of toxicologically 
relevant compounds. 
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4. MATERIALS AND METHODS 
4.1. GENERAL UNKNOWN SCREENING WITH HPLC 
4.1.1. Materials 
Test substances obtained from various pharmaceutical companies were of 
pharmaceutical purity. Organic solvents and reagents were of analytical grade. 
Acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). Solid-
phase extractions (SPE) were carried out on Oasis HLB cartridges (Waters, 
Rupperswil, Switzerland). Deionised water was generated with a Milli-Q water 
purification system from Millipore (Kloten, Switzerland). 
4.1.2. Sample and Buffer Preparation Procedures 
Separate stock solutions were prepared in methanol-water (1:1, v/v) at a concentration 
of 100 µg/mL. Standards in drug free serum (Biorad, Reinach, Switzerland) were 
prepared by spiking stock solutions of drug mixtures to make concentrations ranging 
from 0.250 to 5 µg/mL, resulting in a set of standards with the following 
concentrations: 0.250, 0.500, 1.000, 2.000 and 5.000 µg/mL. 
The buffer (pH 2.2) was prepared with a 20 mmol/L KH2PO4 solution, adjusted to the 
desired pH by appropriate addition of orthophosphoric acid. 
4.1.3. Extraction Procedure 
One ml of serum was acidified by addition of 20 µL phosphoric acid 85%. The solid-
phase extraction (SPE) procedure was carried out on Oasis HLB cartridges. The Oasis 
HLB cartridges were conditioned initially with methanol 1 mL, followed by 1 mL 
Millipore water. 1 mL per serum sample was loaded onto the cartridges. Cartridges 
were subsequently washed with 1 mL Millipore water and dripped dry under charging 
pressure. The compounds of interest were eluted with 1 mL methanol. The extracts 
were evaporated to dryness under a stream of nitrogen and then reconstituted in 1 mL 
of a 10% acetonitrile solution for the general unknown screening. For the 
quantification methods, the extract was solved in the corresponding mobile phase. 
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4.1.4. HPLC-DAD Method 
A Varian Pro Star HPLC system was used for this analysis. It consisted of a Pro Star 
230 solvent delivery module (SDM), a Pro Star 330 PDA Detector, and a Star 
chromatography workstation system with software version 5.50. The analytical 
column used was a LiChrospher 60 RP-select B (5 µm, 125 x 4 mm) protected by a 
LiChrospher 60 RP-select B (5 µm, 4 x 4 mm) both obtained from Merck (Darmstadt, 
Germany). 
 
A HPLC method for the GUS and methods for the quantification of specific substance 
groups were developed. The gradient and the running time was method dependent. 
The HPLC was performed with a gradient of acetonitrile in pH 2.2, 20 mmol/L 
potassium phosphate buffer (for the GUS: 5% ACN for 1 min, increased linearly to 
50% in 14 min, increased linearly to 90% in 3 min, maintained for 4 min) delivered at 
a flow rate of 1.5 mL/min. The method for the GUS was 22 minutes. The injection 
volume was 150 µL in a loop of 20 µL. Detection was performed scanning the 200-
400 nm wavelength range. In-house libraries of spectra of drugs, toxic compounds and 
metabolites were used for compound identification. Table I shows the different 
quantification methods including the running time and the gradient. 
4.1.5. Extraction Recovery Yields 
Drug standard prepared in serum were extracted as previously described. For 
calculation of the recovery yields, the peak area of the compound obtained after the 
extraction was compared with those of standards prepared in methanol and diluted 
with the mobile phase to the appropriate concentrations. 
4.1.6. Identification and Semi-Quantification 
At the completion of the chromatographic procedure, peaks were detected for drugs. 
Peaks were identified based on their relative retention times. The purity and identity of 
each peak was assessed by examination of the UV spectra of the peak in comparison 
to library entries of drugs with similar RTs. 
Concentrations of drugs were calculated by comparing the peak area of the analyte and 
the corresponding standard containing a known amount of the analyte. 
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4.1.7. Quantification 
Quantification methods were developed to determine the extraction recoveries. Table I 
shows the different quantification methods using all the same mobile phase and the 
same column described above. 
 
Table I. Quantification Methods by HPLC for more than 100 Substances.  
substance group method time 
(min) 
phosphate buffer 
(%) 
ACN 
(%) 
Anaesthetics Anaesthetics1 0 
9 
80 
50 
20 
50 
Analgesics Analgesics1 0 
3-7 
90 
60 
10 
40 
 Analgesics2 0 
10 
60 
40 
40 
60 
Antidepressants Antidepressants1 0 
5-8 
75 
50 
25 
50 
Antidiabetics Antidiabetics1 0-9 54 46 
Antiretroviral Antiretroviral1 0-3 
6-12 
70 
30 
30 
70 
Barbiturates Barbiturats1 0 
8-10 
75 
50 
25 
50 
Benzodiazepines Benzodiazepines1 0 
10 
75 
50 
25 
50 
Betablocking Betablocking1 0-1 
5 
7 
10-15 
92 
78 
75 
70 
8 
22 
25 
30 
Coumarines Coumarines1 0-10 50 50 
 Coumarines2 0-10 45 55 
Diuretics Diuretics1 0-1 
10 
95 
80 
5 
20 
 Diuretics2 0-1 
10 
70 
35 
30 
65 
Drugs of Abuse Drugsofabuse1 0-1 
6-10 
90 
60 
10 
40 
Laxatives Laxatives1 0-4 
5-8 
57 
30 
43 
70 
Neuroleptics Neuroleptics1 0 
8 
90 
80 
10 
20 
 Neuroleptics2 0-2 
6 
72 
50 
28 
50 
Stimulants Stimulans1 0-8 80 20 
THC THC1 0-14 40 60 
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4.2. GENERAL UNKNOWN SCREENING WITH MS 
4.2.1. Materials 
Test substances obtained from various pharmaceutical companies were of 
pharmaceutical purity. Organic solvents and reagents were of analytical grade. 
Acetonitrile and methanol were purchased from Merck (Darmstadt, Germany), 
ammonium formate from Aldrich (Steinheim, Germany) and formic acid from Fluka 
(Buchs, Switzerland). Deionised water was generated with a Milli-Q water 
purification system from Millipore (Kloten, Switzerland). HySphere Resin GP 
cartridges were purchased from Spark Holland (Emmen, Netherlands). 
 
The Prospekt 2TM unit from Spark Holland (Emmen, Netherlands) consists of an 
automatic cartridge-exchange module, dual cartridge clamps, solvent delivery unit 
(SDU) (including a high-pressure dispenser (HPD) and solvents). The solvent delivery 
unit is used to condition and wash the cartridges with solvents and to transfer the 
contents of the sample loop of the austosampler into the cartridge. The high-pressure 
dispenser provides the SPE solvents. 
4.2.2. Sample and Buffer Preparation Procedures 
Separate stock solutions were prepared in methanol-water (1:1, v/v) at a concentration 
of 100 µg/mL. Serum standards were prepared by spiking with stock solutions of drug 
mixtures to make concentrations ranging from 0.005 to 4 µg/mL, resulting in a set of 
standards with the following concentrations: 0.005, 0.010, 0.025, 0.050, 0.100, 0.250, 
0.500, 1.000, 2.000 and 4.000 µg/mL. 
 
d3-Benzoylecgonine was prepared as internal standard (IS) at a concentration of 5 
µg/mL. 
 
The pH 3.0 buffer was prepared with a 10 mmol/L ammonium formate solution, 
adjusted to the desired pH by appropriate addition of concentrated formic acid. 
4.2.3. Extraction Procedure 
One ml of serum was acidified by addition of 20 µL concentrated formic acid and 100 
µL of internal standard solution were pipetted into each sample. 
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On-line SPE and elution was performed using the Prospekt 2 system. The HySphere 
Resin GP cartridge was conditioned with 1 mL methanol (5 mL/min) and with 1 mL 
water (5 mL/min). The injection volume was 290 µL in a loop of 100 µL. This 100 µL 
of the serum mixture was loaded on the cartridge. The sorbent was washed with 1 mL 
water (2 mL/min), and eluted with the mobile phase over 15 minutes. Cartridges were 
used only one time in order to avoid contamination. 
4.2.4. Chromatographic and Mass Spectral Conditions 
The chromatographic system consisted of a Rheos 2000 Micro HPLC pump 
(ThermoFinnigan, Allschwil, Switzerland) and a Midas Symbiosis Autosampler from 
Spark (Emmen, Netherlands) equipped with a 100 µL loop. A four-channel degasser 
has been integrated into the Rheos CPS LC System. The LC-MS-MS apparatus was a 
LCQ Advantage MAX from Thermo Finnigan (Allschwil, Switzerland) equipped with 
an APCI device operating in the positive and in the negative detection mode. 
 
The chromatographic separation was performed on a CC Nucleodur C18 Gravity 3 µm 
(4 x 125 mm) with an integrated guard column 3 µm (4 x 8 mm) from Macherey-
Nagel (Oensingen, Switzerland). The mobile phase was delivered at a flow rate of 400 
µL/min. Each chromatographic run was performed with a binary, linear A/B gradient 
(Solvent A was 10 mmol/L ammonium formate, pH 3.0. Solvent B was 90% 
acetonitrile, 10% 10 mmol/L ammonium formate, pH 3.0.). The program was as 
follows: 0-1 min, 6% B; 1-8 min, 6 to 100% B; 8-20 min 100% B; 20-23 min column 
equilibration with 6% B. The solvents were degassed. 
 
A data-dependent acquisition was used, generating a full-scan between 80 and 750 
amu in the first mode. In the second mode a MS-MS spectrum of the most intense ion 
of the previous full-scan was performed. Only this high-intensity ion was kept in the 
ion trap where normalized collision energy is switched on and the resulting fragments 
were analysed. In the positive mode, normalized collision energy was 40.0%, in the 
negative mode 35.0%. The mass spectrometer reverted back to the full-scan mode. 
Dynamic exclusion was enabled. Thirty seconds refractory period was applied to the 
last selected ion. 
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The following APCI inlet conditions were applied. The heated vaporizer was kept at 
465 °C. Both the sheath gas and the auxiliary gas were nitrogen set at 60 and 15 
relative units, respectively. The capillary entrance to the ion trap was at an offset of 28 
V in the positive mode, -4 V in the negative mode and was maintained at 220° C. The 
corona current was 5 µA. Table II shows the data dependent and global data 
dependent settings. 
 
Table II. Data Dependent and Global Data Dependent Settings. 
Data Dependent Settings   
 Default Charge State 1 
 Default Isolation Width 4.0 
 Normalized Collision Energy (%) 40.0 resp. 35.0 
 Min. Signal Required 20000 
Global Data Dependent Settings   
 Exclusion Mass Width 0.5 
 Reject Mass Width 1.0 
 Dynamic Exclusion enabled 
 Repeat Count 1 
 Repeat Duration 0.5 
 Exclusion List Size 25 
 Exclusion Duration 0.5 
 Exclusion Mass Width 0.5 
 
4.2.5. Mass Spectral Library Building Conditions 
Standard solutions were prepared in methanol-water (1:1, v/v) at a concentration of 1-
2 µg/mL. Two mass spectral libraries were created, one for each ionization mode, by 
injecting 20 µL of these solutions directly without HPLC separation into the MS 
system. The MS-MS spectra were obtained at 40.0% normalized collision energy in 
the positive mode and 35.0% normalized collision energy in the negative mode. The 
obtained MS-MS spectra were added to the library. 
 
Relative retention data were acquired by actual LC-MS (-MS) analysis running a 
mixture of each compound with the internal standard. 
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A library was constructed to include per spectra, the name of the compound, the 
molecular formula, and its protonated molecular ion, together with the relative 
retention time. The mass spectral library comprises a total of more than 400 spectra of 
more than 350 compounds. For a semi-quantitative procedure peak areas of the 
compounds (at a concentration of 1 µg/mL) were recorded and attached to the library. 
 
Obtained MS-MS data from a chromatographic run were compared to the MS-MS 
library using the NIST Mass Spectral Program 2.0 from ThermoFinnigan. A computer 
program (XcLibraryScreening) was created to automate the searching process and to 
include the RRT and the molecular ion in the identification of unknown compounds. 
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5. RESULTS AND DISCUSSION 
5.1. SAMPLE PREPARATION AND CHROMATIC CONDITIONS FOR 
A GUS 
The sample preparation must be suitable for various compounds in a large polarity 
range (acidic, neutral and basic). Thus, it requires a nonclass-specific extraction 
procedure able to isolate the widest range of relevant molecules from biological 
matrices. Such procedures may involve a single liquid-liquid extraction, two liquid-
liquid extraction in parallel (one for acidic and neutral and one for basic compounds) 
(51, 54-56), solid-phase extraction with classical hydrophobic phase (49, 57), or mixed-
mode phase SPE (49, 57-60). 
 
SPE was chosen as extraction technique. The SPE mechanism is more selective than 
liquid-liquid extraction. SPE has a number of advantages over liquid-liquid extractions 
such as cleaner extracts, increased selectivity for the compounds of interest, and smaller 
volumes of solvent may be used for extraction. SPE takes less time, and the procedure 
can be automated (11). 
 
A polymer-based sorbent was selected because it is stable over a larger pH range and 
does not have secondary (unbounded hydroxy silanol) groups compared to classical 
hydrophobic phase. 
 
A mixed-mode phase involves both reversed-phase retention and cation-exchange 
properties. The column elution requires two steps. First the acidic and neutral 
substances were eluted with methanol. In the second step the basic substances were 
eluted with a methanol/NH4OH mixture. The acid-neutral and the basic fractions were 
mixed before injection in the HPLC-DAD system in order to save time. 
 
Absolute recoveries were measured for the polymer (Oasis HLB) and the mixed-mode-
based sorbent (Oasis MCX). The Oasis HLB column showed the better extraction 
recoveries for most of the tested substances than the Oasis MCX column. 
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5.1.1. Sample Preparation and Chromatic Conditions with HPLC 
Before loading a sample on the cartridge, 20 µL of orthophoshoric acid (85%) (or 20 
µL of formic acid in the LC-MS method) was added to the sample. The addition of 
acids influenced the protein-binding. The pH was lowered resulting in a disruption of 
the drug-protein interaction yielding better recoveries. Above all, highly-protein bound 
drugs showed a much better recovery. For example the extraction recovery for 
torasemide was improved from 49% to 86%. 
 
For each compound of the library, absolute recovery was measured at least two times 
by extracting and assaying drug-free serum spiked with the drugs tested, then 
comparing the peaks areas of these extracted standards with those of methanolic 
standards at the same concentration. 
 
Of the tested drugs, 94 of 100 were successfully extracted. A successful extraction is 
defined as a recovery of more than 50%. The extraction of more than 50% of the 
tested drugs results in a recovery of more than 90%. Fig. 2 shows the absolute 
recovery of the 100 tested compounds. 
 
This method proved to extract a large range of drugs. Acid, neutrals as well as basic 
drugs were extracted in a satisfying way. Only 6 of the hundred tested drugs showed 
an extraction recovery of less than 50%. These drugs are bromadiolone (extraction 
recovery 31%), chlorophacinone (8%), delta-8-THC (34%), delta-9-THC (47%), 
emodine (40%) and rhein (19%). They are all hydrophobic and mostly of them acidic 
substances. 1 mL of methanol was not sufficient to elute these compounds in a 
satisfying way (≥ 50%) from the column. Improvement of the extraction recovery for 
these substances could be achieved by using a higher volume of methanol, a stronger 
solvent than methanol or another column. Acidic substances were not charged at the 
present pH because of the addition of the ortho-phosphoric acid. Also a change of the 
pH could improve the extraction recovery. 
 
The extraction also proved to be reproducible. Table III shows the extraction recovery 
and coefficient of variation of the 100 tested compounds. The coefficient of variation 
was always less than 15% for all of the compounds with an extraction recovery of 
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more than 50%. The only exception was secobarbital showing a coefficient of 
variation of 16.2%. 
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Fig. 2. Absolute % recovery of the 100 tested compounds with HLB Oasis columns. 
 
Gradient studies were performed to achieve a fast elution ramp without losing too 
much sensitivity and resolution. It was decided that a 5 to 50% acetonitrile gradient 
over 14 minutes, and a 50 to 90% acetonitrile gradient over 3 minutes would be 
suitable for this method. A slow gradient was chosen for the first gradient because 
most of the compounds were eluted in a short time from the column with 50% of 
acetonitrile. These compounds showed a retention time of less than 15 minutes. The 
other substances were eluted with the fast 50-90% acetonitrile gradient. Analytical 
results can be interpreted after 22 minutes. This is an acceptable turnaround time for 
the analysis of emergency drug screening results. In Table III the retention time of 
the 100 substances are listed. 
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Table III. LOD, Recoveries of Drugs and their Coefficient of Variation Using 
the HLB Column and Recorded Retention Time of 100 Compounds. 
Compounds LOD 
(ng/mL) 
Recovery  
(%) 
CV 
(%)  
Retention time 
(min) 
6-acetylmorphine 
acebutolol 
acenocoumarol 
acetaminophen 
acetazolamide 
acetylsalicylic acid 
aloeemodine 
alprazolam 
alprenolol 
amiloride 
amitryptiline 
amobarbital 
amprenavir 
atenolol 
benzoylecgonine 
bisacodyl 
brallobarbital 
bromadiolone 
bupivacaine 
butalbital 
cannabidiol 
cannabinol 
canrenone 
carbromal 
chlordiazepoxide 
chlorophacinone 
chlorthalidone 
cinchocaine 
citalopram 
cocaethylene 
cocaine 
codeine 
coumachlor 
coumaphos 
coumatetralyl 
crimidine 
delta-8-THC 
delta-9-THC 
diazepam 
diclofenac 
dihydrocodeine 
efavirenz 
emodine 
ephedrine 
flupenthixol 
 
1’000 
1’000 
250 
500 
500 
1’000 
500 
1’000 
2’000 
250 
500 
5’000 
1’000 
2’000 
1’000 
500 
5’000 
<ER 
1’000 
2’000 
1’000 
500 
500 
5’000 
250 
<ER 
1’000 
1’000 
2’000 
500 
1’000 
1’000 
500 
1’000 
250 
500 
>2’000 
2’000 
2’000 
1’000 
1’000 
1’000 
1’000 
1’000 
1’000 
 
105 
85 
85 
99 
95 
97 
60 
66 
93 
95 
75 
83 
54 
85 
94 
64 
106 
31 
101 
89 
72 
51 
93 
72 
96 
8 
85 
97 
79 
100 
92 
85 
76 
72 
78 
88 
34 
47 
78 
92 
94 
80 
40 
89 
95 
 
3.5 
2.8 
4.0 
0.9 
2.0 
0.2 
13.2 
14.7 
2.4 
0.7 
4.3 
5.1 
3.0 
1.4 
1.7 
0.5 
1.4 
16.4 
0.8 
0.4 
8.0 
13.0 
4.4 
5.4 
2.0 
56.8 
3.3 
0.5 
2.4 
0.7 
4.7 
2.7 
3.9 
6.2 
1.9 
1.7 
18.0 
12.0 
3.3 
1.4 
4.0 
6.0 
12.9 
2.4 
5.2 
 
6.20 
7.55 
14.99 
3.97 
3.57 
8.53 
13.76 
13.32 
10.57 
4.11 
13.37 
11.43 
14.43 
5.10 
7.42 
12.94 
9.37 
18.39 
10.53 
10.25 
19.25 
19.82 
15.10 
10.97 
9.21 
18.85 
9.20 
12.80 
12.09 
11.15 
9.37 
5.05 
15.93 
18.00 
16.11 
6.57 
20.21 
20.16 
13.83 
15.81 
4.67 
16.86 
16.02 
3.74 
12.53 
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Table III (continued). LOD, Recoveries of Drugs and their Coefficient of 
Variation Using the HLB Column and Recorded Retention Time of 100 
Compounds. 
Compounds LOD 
(ng/mL) 
% 
Recovery 
CV 
(%) 
Retention time 
(min) 
furosemide 
glibenclamide 
glibornuride 
gliclazide 
hydrochlorothiazide 
hydrocodone 
hydromorphone 
ibuprofen 
imipramine 
indinavir 
levomepromazine 
lidocaine 
lopinavir 
lorazepam 
mefenamic acid 
mepivacaine 
methylphenidate 
metoprolol 
morphine 
nadolol 
nalbuphine 
naproxen 
nelfinavir 
nevirapine 
norcodeine 
olanzapine 
oxprenolol 
pentobarbital 
phenobarbital 
phenolphthalein 
phenprocoumon 
pindolol 
propranolol 
propyphenazone 
pseudoephedrine 
quetiapine 
rhein 
ritalinic acid 
ritonavir 
salicylic acid 
saquinavir 
secobarbital 
sertraline 
sotalol 
spironolactone 
 
1’000 
1’000 
1’000 
1’000 
500 
1’000 
500 
1’000 
2000 
1’000 
500 
1’000 
2’000 
1’000 
1’000 
1’000 
2’000 
1’000 
2’000 
5’000 
500 
500 
1’000 
500 
500 
250 
2’000 
5’000 
2’000 
500 
500 
2’000 
1’000 
500 
1’000 
500 
<ER 
1’000 
1’000 
500 
1’000 
5’000 
>2’000 
1’000 
1’000 
 
66 
97 
106 
75 
83 
86 
92 
74 
94 
92 
98 
93 
56 
90 
78 
99 
99 
96 
88 
85 
91 
89 
91 
93 
95 
99 
100 
77 
95 
79 
88 
76 
95 
93 
92 
90 
19 
100 
96 
97 
94 
74 
80 
89 
79 
 
1.8 
1.7 
7.0 
8.6 
0.2 
3.7 
3.8 
1.8 
7.4 
1.9 
0.0 
4.7 
8.9 
5.9 
7.1 
5.1 
1.3 
3.6 
4.7 
8.8 
1.0 
3.4 
2.7 
7.4 
0.9 
1.6 
6.9 
1.0 
2.2 
1.7 
6.3 
10.0 
5.8 
1.8 
2.7 
5.8 
5.0 
1.6 
4.8 
1.9 
2.3 
16.2 
3.0 
4.1 
5.6 
 
12.07 
16.23 
15.23 
14.51 
5.40 
6.36 
3.00 
15.65 
13.02 
10.72 
12.85 
7.38 
16.63 
12.43 
16.65 
7.39 
8.88 
7.83 
3.49 
5.80 
6.70 
13.82 
14.45 
9.76 
4.60 
6.26 
9.09 
11.29 
9.46 
13.19 
15.97 
7.50 
10.43 
12.07 
3.74 
9.74 
14.10 
7.15 
16.34 
9.59 
14.41 
12.07 
13.74 
4.50 
15.67 
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Table III (continued). LOD, Recoveries of Drugs and their Coefficient of 
Variation Using the HLB Column and Recorded Retention Time of 100 
Compounds. 
Compounds LOD 
(ng/mL) 
% 
Recovery 
CV 
(%) 
Retention time 
(min) 
thiopental 
thioridazine 
timolol 
tolbutamide 
torasemide 
trimipramine 
tubocurarine 
venlafaxine 
warfarin 
zuclopenthixol 
 
250 
500 
1’000 
500 
500 
1’000 
500 
1’000 
1’000 
1’000 
 
74 
95 
93 
98 
86 
94 
98 
90 
95 
90 
 
1.1 
4.0 
4.7 
1.7 
1.1 
4.4 
5.7 
9.3 
1.7 
8.8 
 
13.77 
14.35 
7.71 
13.41 
10.64 
13.47 
8.71 
9.96 
14.73 
11.62 
 
 
5.1.2. Sample Preparation and Chromatographic Conditions with LC-MS 
On-line SPE was chosen as an extraction technique because this procedure is 
universal, rapid and can be automated. This method is becoming popular in 
bioanalytical analysis (61). The Prospekt solid phase extraction can be linked to the 
APCI ion source of the LC-MS-MS instrument (62). The system couples and 
automates sample extraction and instrumental analysis. Benefits of this technology 
include improved precision of all extraction steps. This method has a time saving 
advantage compared to other techniques because vaporizing the sample extract is not 
necessary. In addition, the procedure presented in this study extracts acidic, neutral as 
well as basic drugs. 
 
The chromatographic conditions (column and mobile phase) must be chosen in an 
appropriate way. The most polar must be retained and the most lipophilic compounds 
must be eluted. The mobile phases must be compatible with API sources. 
 
Most of the HPLC-DAD applications use non-volatile buffers such as phosphate and 
borate buffers. These non-volatile buffers cause problems in combination with MS and 
should be avoided. They are blocking the capillary in the probe, and are causing salt 
buildup on the spray head and thus compromise the integrity of the spray. Volatile 
buffers like ammonium acetate, ammonium formate, acetic acid and ammonium 
carbonate buffers can be used instead. Ammonium formate was chosen because of its 
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suitability as a buffer at a pH of 3. Ammonium is necessary for a better elution of the 
compounds in combination with the Prospekt and often avoids the tailing of peaks. 
 
An appropriate column has to be chosen in combination with the Prospekt. The 
column has to retain all the compounds stronger than the extraction column of the 
Prospekt to obtain a satisfying chromatography. A C18 Nucleodur Gravity column was 
chosen because of its capability to be linked with the Prospekt, its stability within a 
large pH range and its robustness. 
 
The separation of the drugs was carried out under acidic conditions (pH = 3) in order 
to limit secondary interaction on the free silanol groups of the C18 column. The first 
peak eluted at 5.9 minutes (morphine) and the last at 18.4 minutes (delta-8-THC). The 
absolute retention times are shown in Table IV. Separation of substances is necessary 
to detect low-level analytes. Ionization of mobile phase components (acetonitrile, 
ammonium formate) and endogenous compounds is the main source of background 
noise. Contamination of the mass spectra by these compounds potentially hampers the 
identification of low concentrations of analytes. The screening of a sample can be 
performed in less than one hour with a chromatographic run taking 23 minutes for 
each mode (positive and negative), which is an acceptable analytical time for a GUS 
(including library search and interpretation). 
 
APCI and ESI were compared with each other in order to examine with which ion 
source the higher signals were detected. More than hundred compounds were 
investigated in aqueous solutions. 
 
In summary, higher signals were detected with APCI for hydrophobic substances like 
cannabinoids or coumarines and acidic drugs. Better results were obtained with ESI 
for basic drugs such as neuroleptics and antidepressants. Basic drugs are positively 
charged at a pH of 3.0 (pH of the mobile phase). 
 
These results are not astonishing. The relation of the molecular mass range and the 
polarity of analytes that can be analyzed by GC-MS, APCI LC-MS and ESI LC-MS 
techniques are sketched in Fig. 3. APCI allows sensitive determination of analytes 
with moderate polarity and molecular mass. ESI enables the better determination of 
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analytes of high molecular mass (up to several hundred units such as peptides or 
proteins) and high polarity. 
 
Table IV. Recorded LC Retention Times of 87 Compounds. 
Compounds Retention time 
(min) 
Compounds Retention time 
(min) 
morphine 
amiloride 
atenolol 
hydromorphone 
sotalol 
codeine 
dihydrocodeine 
norcodeine 
6-acetylmorphine 
acetaminophen 
olanzapine 
hydrocodone 
pseudoephedrine 
ephedrine 
nadolol 
tubocurarine 
nalbuphine 
benzoylecgonine 
acetazolamide 
ritalinic acid 
pindolol 
mepivacaine 
acebutolol 
timolol 
lidocaine 
metoprolol 
cocaine 
oxprenolol 
hydrochlorothiazide 
venlafaxine 
cocaethylene 
bupivacaine 
propranolol 
alprenolol 
chlorthalidone 
quetiapine 
indinavir 
torasemide 
citalopram 
levomepromazine 
nevirapine 
chlordiazepoxide 
flupenthixol 
cinchocaine 
 
5.89 
6.10 
6.10 
6.16 
6.25 
6.30 
6.42 
6.42 
6.51 
6.53 
6.53 
6.55 
6.55 
6.56 
6.60 
6.67 
6.76 
6.77 
6.81 
6.86 
6.89 
7.00 
7.05 
7.05 
7.06 
7.19 
7.27 
7.32 
7.43 
7.45 
7.50 
7.76 
7.76 
7.79 
7.80 
7.88 
7.92 
7.99 
8.02 
8.02 
8.08 
8.17 
8.33 
8.39 
 
imipramine 
phenobarbital 
amitryptiline 
canrenone 
trimipramine 
brallobarbital 
nelfinavir 
sertraline 
zuclopenthixol 
saquinavir 
thioridazine 
crimidine 
furosemide 
phenolphthalein 
alprazolam 
lorazepam 
propyphenazone 
amprenavir 
tolbutamide 
rhein 
aloeemodine 
acenocoumarol 
gliclazide 
warfarin 
glibornuride 
bisacodyl 
glibenclamide 
ritonavir 
diazepam 
lopinavir 
phenprocoumon 
diclofenac 
coumachlor 
coumatetralyl 
efavirenz 
emodine 
mefenamic acid 
bromadiolone 
chlorophacinone 
cannabidiol 
cannabinol 
delta-9-THC 
delta-8-THC 
 
 
8.40 
8.45 
8.48 
8.48 
8.55 
8.56 
8.57 
8.58 
8.58 
8.61 
8.93 
8.97 
8.97 
9.08 
9.16 
9.28 
9.67 
9.80 
9.80 
10.30 
10.34 
10.40 
10.49 
10.53 
10.57 
10.59 
10.73 
10.82 
10.87 
10.89 
10.91 
11.11 
11.12 
11.17 
11.58 
11.65 
12.05 
12.85 
13.78 
14.15 
16.58 
18.23 
18.44 
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Fig. 3. Relation of the molecular mass range and the polarity of analytes analyzable by 
GC-MS and LC-MS interface techniques (APCI and ESI). 
 
This was confirmed by Bogusz et al. They showed that between these two ionization 
sources, atmospheric pressure chemical ionization appeared more universal and 
assured generally higher sensitivity. Only in the case of very polar drugs (e.g. psilocin 
or psilocybin) electrospray ionization was more sensitive (63). 
 
For a GUS it is not necessary to detect high molecular mass. Most of drugs have 
masses under 500 amu and are moderately polar. But at an acidic pH (required in this 
method) a lot of compounds are positively charged and become more polar. None of 
the two ion sources showed a large benefit in this examination. 
 
APCI was preferred to electrospray ionization in order to reduce ion suppression. This 
phenomenon affects the amount of charged ion in the gas phase that reaches the 
detector. Although ion suppression can have effects on both electrospray ionization 
and atmospheric pressure chemical ionization, evidence indicates that the electrospray 
interface is more impacted. Experiments have shown that with the same extraction 
procedure and method ESI was more affected by ion suppression than APCI. Serums 
or aqueous solutions were spiked with the same amount of a compound. Ionization 
with ESI resulted in a large variability between the matrix specimen and the aqueous 
solution. The signal of the analyte in serum was mostly decreased. The extent of the 
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ion suppression is not being predictable. In a GUS ion suppression is responsible for 
higher LODs. In the worst case ion suppression can result in false negative results. 
 
5.2. LIBRARY SCREENING AND QUANTIFICATION 
5.2.1. Identification with HPLC 
The present method allows easy and rapid identification of 100 substances belonging 
to different pharmacological classes. The LOD of all the substances are listed in Table 
III. 
 
UV spectra and retention time databases were established by spiking aqueous with 
pure drugs for the identification of drugs extracted from serum. Bogusz et al showed 
that the co-extracted biological matrix did not exert any influence on the 
chromatographic behaviour of drugs analyzed by means of gradient HPLC (28). 
 
Serum samples spiked with decreasing concentrations of the tested drugs were 
analyzed in order to determine LODs. Each concentration was extracted and analysed 
two times. The LOD was set at the lowest concentration where the signal of the 
compound was three times higher than the background noise and the spectral 
similarity was above the cut-off (> 0.9). 
 
Identification of drugs with diode array detection and a spectrum library are affected 
by the presence of co-extracted matrix substance. These compounds can co-elute at the 
same time as toxicologically relevant substances and overlap the corresponding UV 
spectra. The purity of the extract is therefore important for a successful HPLC-DAD 
identification of a drug even at small concentrations. 
 
In order to increase the specificity of the method, each drug of the library is also 
characterized by its retention time. The retention time has to be in a time window of ± 
0.5 min. Identification errors require coincidence of both RTs and UV spectra. 
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The LOD was set at the lowest concentrations where both samples fulfilled the 
mentioned requirements (spectra similarity and retention time). The limit of detection 
(LOD) for the majority of the tested drugs (76%) was ≤ 1’000 ng/mL. 
 
Shifts of the retention time of compounds are characteristics of changes in the molarity 
or pH of the mobile phase or ageing of the column. Also two columns of the same 
brand can cause a shift of the retention time. 
 
The use of retention times relative to an internal standard reduces the influence of the 
altering of the column or changing the column. Relative retention time is more 
reproducible than the retention time. Bogusz et al showed that relative retention time 
data can be used interlaboratory (64, 65). With this procedure the retention time can be 
corrected and is less affected by the mentioned influences. 
5.2.2. A Semi-Quantitative Procedure with HPLC 
Not only the identification of compounds is important, also the determination of the 
concentration is crucial in a GUS to estimate the severity of the intoxication. A semi-
quantitative procedure was performed. Drug-free serum spiked with the drugs tested 
were extracted and analyzed. Peak areas of extracted serum sample were compared to 
peak areas of methanolic standards of the database considering the extraction 
recovery. Results are shown in Table IV. The measured concentration of 72 of totally 
94 substances was within 20%. These results indicated the possibility to estimate the 
drug concentration with this procedure. 
 
Co-extracted matrix substances affect the quantitation of drugs eluting at the same 
time. This is one of the major causes of errors in chromatographic analysis. An 
erroneous result can be caused by a coeluting matrix substance that mimics the 
spectrum of a compound listed in Table V or interfere with the detection of a part of a 
peak. 
 
The basis of the assay was to provide a means to identify a drug or poison and an 
estimate of its concentration. More accurate quantitation was then conducted using the 
quantification method. 
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Table V. Extraction rate of spiked serum samples compared to methanolic 
standard concentrations. 
Drug Measured 
(µg/mL) 
Difference 
(%) 
Drug Measured 
(µg/mL) 
Difference 
(%) 
6-acetylmorphine 
acebutolol 
acenocoumarol 
acetaminophen 
acetazolamide 
acetylsalicylic acid 
aloeemodine 
alprazolam 
alprenolol 
amiloride 
amitryptiline 
amobarbital 
amprenavir 
atenolol 
benzoylecgonine 
bisacodyl 
brallobarbital 
bupivacaine 
butalbital 
cannabidiol 
cannabinol 
canrenone 
carbromal 
chlordiazepoxide 
chlorthalidone 
cinchocaine 
citalopram 
cocaethylene 
cocaine 
codeine 
coumachlor 
coumaphos 
coumatetralyl 
crimidine 
diazepam 
diclofenac 
dihydrocodeine 
efavirenz 
ephedrine 
flupenthixol 
furosemide 
glibenclamide 
glibornuride 
gliclazide 
hydrochlorothiazide 
 
0.99±0.28 
2.22±0.33 
0.57±0.01 
4.19±0.30 
0.95±0.00 
1.16±0.16 
2.02±0.10 
0.53±0.11 
1.85±0.21 
0.71±0.04 
1.46±0.32 
2.28±0.40 
1.22±0.05 
2.05±0.05 
1.17±0.00 
1.44±0.00 
4.67±0.07 
0.80±0.04 
1.94±0.06 
0.54±0.01 
1.18±0.08 
0.99±0.02 
6.29±0.11 
0.46±0.01 
1.01±0.15 
1.05±0.16 
2.00±0.03 
1.02±0.01 
0.97±0.06 
1.14±0.01 
0.99±0.08 
1.09±0.06 
0.97±0.06 
1.01±0.11 
1.74±0.28 
4.29±0.36 
0.77±0.07 
1.04±0.13 
0.92±0.01 
1.04±0.13 
1.00±0.05 
0.92±0.01 
0.84±0.06 
1.16±0.21 
1.00±0.13 
 
-0.8% 
10.9% 
14.8% 
-16.3% 
-4.8% 
-41.9% 
0.8% 
-46.5% 
-7.4% 
-29.0% 
45.8% 
-54.3% 
21.5% 
2.5% 
17.5% 
44.3% 
-6.7% 
-19.8% 
-3.0% 
-46.4% 
-40.9% 
-1.2% 
25.7% 
-7.8% 
1.2% 
5.4% 
-0.1% 
2.2% 
-2.6% 
14.3% 
-0.8% 
8.9% 
-2.9% 
0.8% 
-13.1% 
-14.3% 
-22.5% 
3.9% 
-8.2% 
-16.0% 
16.4% 
-0.5% 
-25.2% 
-10.4% 
13.0% 
 
hydrocodone 
hydromorphone 
ibuprofen 
imipramine 
indinavir 
levomepromazine 
lidocaine 
lopinavir 
lorazepam 
mefenamic acid 
mepivacaine 
methylphenidate 
metoprolol 
morphine 
nadolol 
nalbuphine 
naproxen 
nelfinavir 
nevirapine 
norcodeine 
olanzapine 
oxprenolol 
pentobarbital 
phenobarbital 
phenolphthalein 
phenprocoumon 
pindolol 
propranolol 
propyphenazone 
pseudoephedrine 
quetiapine 
ritalinic acid 
ritonavir 
salicylic acid 
saquinavir 
secobarbital 
sertraline 
sotalol 
spironolactone 
thiopental 
thioridazine 
timolol 
tolbutamide 
torasemide 
trimipramine 
 
0.70±0.12 
0.98±0.16 
6.54±0.08 
1.80±0.20 
0.94±0.03 
0.96±0.01 
0.88±0.11 
1.57±0.09 
1.09±0.02 
1.42±0.02 
1.13±0.02 
1.93±0.05 
0.92±0.11 
1.79±0.18 
5.28±0.62 
1.12±0.27 
5.71±0.12 
1.13±0.03 
0.86±0.08 
0.89±0.01 
0.69±0.13 
1.99±0.31 
4.66±0.11 
1.73±0.08 
1.74±0.02 
0.47±0.04 
1.17±0.40 
1.04±0.00 
4.79±0.04 
0.81±0.25 
1.07±0.22 
0.79±0.03 
0.52±0.00 
4.27±0.13 
0.83±0.02 
4.28±0.74 
4.15±0.36 
1.86±0.25 
0.69±0.02 
0.58±0.00 
1.12±0.21 
1.03±0.01 
0.81±0.04 
1.09±0.05 
0.86±0.18 
 
-29.7% 
-2.4% 
30.8% 
-9.8% 
-5.7% 
-4.1% 
-11.7% 
-21.3% 
9.2% 
-28.9% 
12.9% 
-3.5% 
-7.9% 
-10.3% 
5.7% 
12.2% 
14.3% 
12.7% 
-14.5% 
-10.9% 
-30.7% 
-0.3% 
16.6% 
-13.7% 
-13.0% 
-5.1% 
-41.3% 
4.3% 
-4.3% 
-19.2% 
6.9% 
-20.7% 
-48.4% 
-14.6% 
-17.3% 
-14.4% 
38.3% 
-7.2% 
-31.4% 
16.7% 
12.2% 
3.2% 
-18.7% 
8.8% 
-13.6% 
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Table V (continued). Testing of the Semi-Quantitative General Unknown 
Screening procedure. 
Drug Measured 
(µg/mL) 
Difference 
(%) 
Drug Measured 
(µg/mL) 
Difference 
(%) 
tubocurarine 
venlafaxine 
 
1.19±0.18 
1.14±0.09 
 
19.3% 
13.9% 
 
warfarin 
zuclopenthixol 
 
0.80±0.20 
0.88±0.21 
 
-20.3% 
-12.3% 
 
 
5.2.3. Method Development 
MS-MS data results higher specificity and selectivity and more structural information 
for the identification of an unknown substance. First the unknown compound has to be 
detected. In the second step a product-ion scan has to be applied. This procedure is not 
compatibile for a GUS with the classic MRM mode. Mass spectra recorded with in-
source CID don’t result from a single parent ion resulting in low specificity and 
selectivity. 
 
The method of choice was a data-dependent acquisition procedure. In the first step 
(so-called "survey scan") the MS-MS instrument is operated in the full-scan single-
mass mode. In the second mode the most intense ion above a predefined threshold was 
selected. This ion was fragmented in the collision cell. The resulting fragments were 
analyzed in the scan mode. 
 
A refractory period was set to the last ion selected for 30 seconds. Less intense ions of 
compounds eluting at the same time would not be detected without a refractory period. 
A refractory period longer than 30 seconds can result in a loss of identification of a 
compound with the same molecular mass ion. With a shorter refractory period the 
method can fail to detect substances eluting at the same time. After a short time the 
instrument switched back to the initial conditions. 
 
Mass spectra data were established by spiking methanol-water (1:1; v/v) with pure 
drugs for the identification of drugs extracted from serum. Mass spectra were recorded 
in the negative as well as in the positive mode; because some substances can only be 
detected in one mode or they have different LOD for both modes. For example 
morphine was better detected with the positive mode, bromadiolone better detected in 
the negative mode. For both modes a library was created. In best cases, substances 
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with positive and negative spectra can be identified in both modes with the respective 
libraries. So results from both libraries confirm each other in most cases. 
 
The MS-MS spectra were obtained at 40.0% normalized collision energy in the 
positive mode and 35.0% normalized collision energy in the negative mode. Examples 
of product ion mass spectra are shown in Fig. 4 and Fig. 5. The MS-MS spectrum of 
cocaine in the positive and the spectrum of saquinavir in the negative mode are 
presented. The normalized collision energies of 40.0% in the positive and 35.0% in the 
negative mode were chosen in order to obtain fragmentation of the compounds. A 
decrease of the normalized collision energy would yield less fragmentation. Applying 
higher normalized collision energy would result in much lower peak intensities of the 
fragments. 
 
 
Fig. 4. MS-MS spectrum of cocaine obtained in the positive mode with normalized 
collision energy of 40.0%. 
 
 
 
Fig. 5. MS-MS spectrum of saquinavir obtained in the negative mode with normalized 
collision energy of 35.0%. 
 
The relative retention time data were gathered by running a mixture of each compound 
with the internal standard by an actual LC-MS (-MS) analysis. 
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A library was constructed to include per spectra, the name of the compound, the 
molecular formula, and its protonated molecular ion, together with its relative 
retention time. This mass spectral library comprises spectra of drugs and metabolites 
from a large diversity of substance classes. With this procedure acidic, neutral as well 
as basic drugs can be detected and identified. 
5.2.4. Automatic Library Searching with LC-MS 
 
A small application program was developed for the automated identification of 
unknown compounds with LC-MS. 
 
In order to identify unknown compounds in a serum sample a chromatographic run 
was performed in each mode. In the next step the developed program compared each 
recorded MS-MS spectrum to those in the library from the Xcalibur software. With 
this program the number of best hits that the unknown spectrum should be compared 
to can be specified. In the procedure described in this study the ten best hits were 
chosen. 
 
In the presented example a run was loaded of a serum sample spiked with 5 substances 
(Fig. 6). The run was performed in the positive mode. Phenolphthalein, gliclazide, 
bisacodyl, glibornuride and glibenclamide were added to a serum sample at a 
concentration of 1 µg/mL. 
 
The similarity between the library spectra and the unknown spectra is characterized by 
the match factor and the reverse match factor. The match factor indicates the 
correlation between the unknown spectrum and the library spectrum (presence and 
relative intensities of mass-to-charge ratios). The reverse match factor indicates an 
inverse search. The presence and the relative intensity of the ions of the library 
spectrum are compared to those of the unknown spectrum. This parameter ignores the 
ions present in the unknown spectrum if absent in the reference spectrum. 
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Fig. 6. All MS-MS spectra were loaded from a run. They were compared to the 
spectra in the library. 
 
The match factor and the inverse match factor range between 0 and 1’000 with 0 
indicating no similarity and 1’000 indicating perfect similarity. In our procedure for 
both factors the threshold was set at 400. With this threshold parameter the best results 
were obtained. It is also possible to set another threshold. A higher threshold can result 
in a higher LOD and in a more specific result. A lower threshold can result in false 
negatives but also in a lower LOD. 
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Fig. 7. Comparison of the positive MS-MS spectrum of glibornurid in a serum sample 
using DDA to the MS-MS spectrum of the library. 
 
Each product ion mass spectrum was subjected to an automated library searching 
routine compared to the library spectra. Fig. 7 shows the MS-MS spectrum of 
gliclazide from spiked serum (above in red colour) obtained with this procedure 
compared to the MS-MS spectrum of the library (below in blue colour). The match 
factor of the presented mass spectra was 889, the reverse match factor was 989. 
 
Compound identification took in account the mass-to-charge ratio of the unknown 
compound selected before fragmentation. This mass-to-charge ratio has to be within ± 
2 m/z of the reference mass-to charge ratio recorded in the library. The width of the 
mass-to-charge ratio window was chosen to include the isotopes of the compound. 
 
The pseudomolecular ion (usually, protonated in the positive mode, deprotonated in 
the negative mode) and its fragments were obtained and compared to references in the 
library. Each MS-MS spectrum recorded is derived from one single mass-to-charge 
ratio (representing the most intense ion of the previous full scan). 
 
Other authors used collision-induced dissociation at different voltages to obtain the 
same information. Mass spectra were acquired by continuously switching between a 
low and a high orifice voltage throughout the run to obtain both protonated molecular 
ion (low-voltage scan) and mass spectral fragments (high voltage scan) from the CID 
in the ion source. The low-voltage spectrum was dominated by the pseudomolecular 
ion, whereas the high-voltage spectrum contained mass fragment ions. Mass spectra 
from the two different voltage scans were then summed to produce a mass spectrum 
MS-MS spectrum using DDA 
Library MS-MS spectrum 
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for each compound in the library in order to maximize the information. With the 
procedure presented in this study it is not necessary to switch between different orifice 
voltages. 
 
RRT was also included in the identification procedure. The RRT of the unknown 
compound has to be within ± 5%. This large time-window was chosen because the 
MS-MS spectra can be obtained during the whole peak width and the refractory period 
was set at 30 s. The RT of the IS was registered in the positive mode with a value of 
approximately 6.9 min. Variations in RT occur when using different lots of columns 
with the same absorption material. 
 
Only if all the parameters were within the fixed areas a hit was reported. In summary 
the match factor and the reverse match factor had to be above 400, the mass-to-charge 
had to be ± 2 m/z and the RRT had to be within 5% (Fig. 8). Each MS-MS spectrum, 
which fulfilled these conditions, was reported. 
 
The report consists of the different hits with their names, together with the match 
factor and reverse match factor of the comparison with the library spectrum, relative 
retention time and mass-to-charge in this run and the one in the library. 
 
The new program automatically releases a report, which consists of the different hits 
with the substance names, together with the match factor, the reverse match factor, the 
RRTs and mass-to-charge relations compared to the ones in the library. 
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Fig. 8. The library search parameters and the library can be specified. In this method 
the threshold of the match factors were set at 400, the RRT has to be within ± 5% and 
the maximum deviation of the mass-to-charge was two. It was allowed to return the 
ten best hits. 
 
All 5 substances in a concentration of 1 µg/mL were identified with our procedure. 
Fig. 9 shows the output generated by the LC-MS-MS and the software. Gliclazide, 
bisacodyl, glibornuride and glibenclamide all have similar retention times. However, 
this was a minor problem because a refractory period was applied enabling to identify 
the compounds even though they were not chromatographically separated. 
Importantly, the co-eluting substances did not affect the MS-MS spectra in the 
presented procedure in contrast to single MS CID methods. Therefore, the analysis of 
unknown compound is more rapid using MS-MS. 
 
Spectra obtained using MS with in source-CID are mostly identically as those 
produced by conventional MS-MS CID. But these MS spectra would be affected by 
co-eluting substances. 
Results and Discussion 
57 
 
 
Fig. 9. In this result file the different hits are presented with their substance name, 
match factor, reverse match factor, RRT and mass-to-charge relation compared to the 
corresponding parameters in the library. The same substance can be found several 
times with different MS-MS spectra. 
 
Serum samples spiked with decreasing concentrations of the tested drugs were 
analyzed in order to determine LODs. Each concentration from 0.005 to 4 µg/mL was 
extracted and analyzed two times. The LOD was set at the lowest concentrations 
where both samples fulfilled the mentioned requirements to identify a compound and 
hits were reported. The compounds were listed as hits by the small application 
program. 
 
Out of 100 tested compounds, only 13 (amobarbital, acetylsalicylic acid, butalbital, 
carbromal, coumaphos, ibuprofen, methylphenidate, naproxen, pentobarbital, salicylic 
acid, secobarbital, spironolactone and thiopental) were not detectable with this LC-MS 
method. These compounds were identified neither at high therapeutic concentrations 
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nor at low toxic concentrations with the described method. Most of the undetectable 
drugs were acidic compounds belonging to the class of analgesics or barbiturates. 
Generally these compounds have high serum concentrations and can easily be detected 
with HPLC-DAD. 
 
Therapeutic and toxic serum concentration are listed in a review of Schulz et al (66). 
These data were taken as an orientation where the therapeutic concentration ended and 
the toxic concentration began. In general, therapeutic plasma concentration ranges or 
concentrations found after therapeutic dosing refer to trough levels at steady state. For 
a specific patient, it is often not possible to find the threshold between the therapeutic 
and toxic concentration. This is the case if tolerance develops and if drug interactions 
or additional diseases are involved. 
 
Table VI shows the different LODs for 87 compounds detected either in the positive 
and/or in the negative mode. With our procedure all these compounds could be 
detected at high therapeutic drug concentration or at concentrations in the low toxic 
range. LOD was ≤ 100 ng/mL for 67% of the compounds. Most of drugs were better 
detected in the positive mode, especially compounds with chemical structures of 
amines such as neuroleptics, opioids and anti-depressants. In the negative mode a 
lower LOD was seen with molecules containing acidic sites like diclofenac. 
 
For routine screening the combination of SPE, LC and APCI-MS represents an 
attractive alternative to the well-established technique of GC-MS. The SPE-APCI-MS 
screening method demonstrated to be suitable for routine measurements of serum 
samples. The method is highly specific because the substances are identified by their 
retention times, their molecular ions and characteristic fragments. 
 
Rapid identification in screening experiments was achieved by the creation of the 
small application program. This program incorporates mass spectra data, molecular 
ions and retention time. With the presented method, the analysis of 1 serum sample 
can be performed in less than an hour. 
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Table VI. LODs in Serum Determined for 87 Drugs Applying Negative and Positive 
Ionization Mode. 
 LOD (ng/mL)  LOD (ng/mL) 
 positive  negative  positive negative 
6-acetylmorphine 
acebutolol 
acenocoumarol 
acetaminophen 
acetazolamide 
aloeemodine 
alprazolam 
alprenolol 
amiloride 
amitryptiline 
amprenavir 
atenolol 
benzoylecgonine 
bisacodyl 
brallobarbital 
bromadiolone 
bupivacaine 
cannabidiol 
cannabinol 
canrenone 
chlordiazepoxide 
chlorophacinone 
chlorthalidone 
cinchocaine 
citalopram 
cocaethylene 
cocaine 
codeine 
coumachlor 
coumatetralyl 
crimidine 
delta-8-THC 
delta-9-THC 
diazepam 
diclofenac 
dihydrocodeine 
efavirenz 
emodine 
ephedrine 
flupenthixol 
furosemide 
glibenclamide 
glibornuride 
gliclazide 
 
100 
100 
 
500 
 
 
50 
250 
100 
25 
50 
25 
50 
100 
 
1000 
250 
100 
250 
50 
100 
 
1000 
25 
100 
500 
100 
100 
500 
1000 
250 
100 
100 
250 
1000 
25 
 
 
500 
100 
 
25 
100 
250 
 
 
 
25 
 
2000 
50 
 
 
 
 
50 
 
 
 
1000 
250 
 
 
 
 
 
50 
 
 
 
 
 
 
50 
100 
 
 
 
 
500 
 
100 
50 
 
 
100 
50 
100 
100 
 
hydrochlorothiazide 
hydrocodone 
hydromorphone 
imipramine 
indinavir 
levomepromazine 
lidocaine 
lopinavir 
lorazepam 
mefenamic acid 
mepivacaine 
metoprolol 
morphine 
nadolol 
nalbuphine 
nelfinavir 
nevirapine 
norcodeine 
olanzapine 
oxprenolol 
phenobarbital 
phenolphthalein 
phenprocoumon 
pindolol 
propranolol 
propyphenazone 
pseudoephedrine 
quetiapine 
rhein 
ritalinic acid 
ritonavir 
saquinavir 
sertraline 
sotalol 
thioridazine 
timolol 
tolbutamide 
torasemide 
trimipramine 
tubocurarine 
venlafaxine 
warfarin 
zuclopenthixol 
 
 
50 
50 
500 
25 
400 
250 
50 
100 
250 
100 
250 
50 
50 
50 
25 
50 
100 
250 
250 
 
50 
500 
100 
100 
50 
100 
50 
 
500 
50 
10 
250 
25 
500 
100 
 
100 
250 
100 
250 
250 
100 
 
4000 
 
 
 
250 
 
 
25 
100 
250 
 
 
 
 
 
100 
 
 
 
 
2000 
 
50 
 
 
 
 
 
50 
 
 
25 
 
 
 
 
250 
 
 
 
 
25 
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5.2.5. A Semi-Quantitative Procedure with LC-MS 
The chosen procedure enables to perform a semi-quantitative analysis. In a general 
unknown procedure it is not only important to determine the drugs potentially 
responsible for the toxic effect but also the approximate concentration of the 
compound. In the described procedure most of the compounds were detected at 
therapeutic concentrations. Some of the drugs like atenolol can even be identified at 
levels lower than the therapeutic concentration. Therefore, it is important to quantify 
the present drug in a GUS to have a first reference to the severity of the intoxication.  
 
In the chosen program at least every second event is a full scan. A quantitative result 
of any compound can be calculated with the corresponding extracted ion 
chromatogram. Fig. 10 and 11 give an overview of all the extracted ion chromato-
grams of water sample extracted according the solid-phase extraction procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 10. XIC chromatograms of aqueous solutions spiked with compounds. 79 
compounds are displayed in the positive mode. 
chlordiazepoxide 
metoprolol 
timolol 
sotalol 
alprenolol 
oxprenolol 
nadolol 
acebutolol 
propranolol 
pindolol 
atenolol m/z = 267.2 
m/z = 310.2 
m/z = 249.2 
m/z = 260.2 
m/z = 266.2 
m/z = 337.2 
m/z = 273.0 
m/z = 300.1 
m/z = 250.3 
m/z = 317.1 
m/z = 268.2 
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Fig. 10 (continued). XIC chromatograms of aqueous solutions spiked with 
compounds. 79 compounds are displayed in the positive mode. 
amitryptiline 
imipramine 
quetiapine 
trimipramine 
citalopram 
olanzapine 
delta-9-THC 
11-nor-delta-THC-COOH 
cannabidiol 
cannabinol 
delta-8-THC 
tubocurrarine 
ritalinic acid 
acetamionphen 
methylphenidate 
ephedrine 
pseudoephedrine 
morphine 
hydrocodone 
norcodeine 
dihydrocodeine 
torasemide 
canrenon 
 
chlorthalidone 
amiloride 
gliclazide 
glibornuride 
glibenclamide 
bisacodyl 
phenolphthaleine 
lorazepam 
4-OH-midazolam 
diazepam 
alprazolam 
m/z = 234.1 
m/z = 609.3 
m/z = 166.3 
m/z = 220.3 
m/z = 152.1 
m/z = 311.1 
m/z = 345.1 
m/z = 166.3 
m/z = 315.2 
m/z = 315.2 
m/z = 278.2 
m/z = 315.1 
m/z = 295.2 
m/z = 313.2 
m/z = 281.2 
m/z = 325.2 
m/z = 384.3 
m/z = 321.2 
m/z = 324.2 
m/z = 300.1 
m/z = 343.1 
m/z = 285.3 
m/z = 494.0 
m/z = 230.1 
m/z = 367.1 
m/z = 362.2 
m/z = 319.1 
m/z = 359.2 
m/z = 349.0 
m/z = 302.3 
m/z = 286.5 
m/z = 321.2 
m/z = 286.3 
m/z = 300.6 
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Fig. 10 (continued). XIC chromatograms of aqueous solutions spiked with 
compounds. 79 compounds are displayed in the positive mode. 
crimidine 
warfarin 
coumachlor 
phenprocoumon 
coumatetralyl 
bromadiolone 
6-acetylmorphine 
cocaethylene 
benzoylecgonine 
cocaine 
hydromorphone 
codeine 
nalbuphine 
bupivacaine 
cinchocaine 
lidocaine 
mepivacaine 
venlafaxine 
zuclopenthixol 
levomepromazine 
flupenthixol 
thioridazine 
d3-benzoylecgonine 
sertraline 
propyphenazone 
amprenavir 
mefenamic acid 
diclofenac 
ritonavir 
saquinavir 
nelfinavir 
nevirapine 
indinavir     
lopinavir 
m/z = 267.3 
m/z = 721.1 
m/z = 614.3 
m/z = 568.5 
m/z = 671.3 
m/z = 506.1 
m/z = 296.0 
m/z = 629.1 
m/z = 306.1 
m/z = 231.2 
m/z = 278.2 
m/z = 242.2 
m/z = 435.2 
m/z = 293.2 
m/z = 401.2 
m/z = 317.5 
m/z = 329.1 
m/z = 235.1 
m/z = 304.1 
m/z = 247.1 
m/z = 289.2 
m/z = 344.1 
m/z = 300.3 
m/z = 318.1 
m/z = 286.4 
m/z = 358.4 
m/z = 290.2 
m/z = 172.2 
m/z = 328.3 
m/z = 281.1 
m/z = 510.9 
m/z = 309.1 
m/z = 293.3 
m/z = 343.1 
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Fig. 11. XIC chromatograms of aqueous solutions spiked with compounds in the 
negative mode. 29 compounds are displayed in the negative mode. 
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Fig. 10 shows the extracted ion chromatograms of 79 compounds detected in the 
positive mode, Fig. 11 shows the chromatograms of 29 compounds detected in the 
negative mode. Peak areas of the compounds spiked in serum (at a concentration of 1 
µg/mL) were recorded and the area ratios (peak area of the compound relative to the 
peak area of the IS) were attached to the library together with the RRTs and the 
corresponding molecular ions (Table VII). Concentration of unknown compounds can 
be determined with the area ratio. 
 
Concentrationunknown compound (µg/mL)= Areaunknown compound / (Area Ratio * AreaIS ) 
 
Further studies have to be done to approve the performance of the quantitative 
analysis. The ionization process can be more affected for certain substances than for 
others. In this study only one internal standard was applied, therefore a precise 
quantification is not possible. But preliminary semi-quantitative experiments are 
promising. This fits perfectly into the picture of screening procedures.  
Most of the GUS described yet provide only a qualitative result (44, 48, 53). A 
specific quantitative procedure has to be performed in addition. 
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Table VII. Relative Retention Times (RRT), Molecular Ions, and Area Ratios (Area 
Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion Area Ratio 
1 10,11-dihydro-10-OH-carbamazepine 1.11 255.0 0.89 
2 11-nor-delta-THC-COOH 1.86 345.1 0.80 
3 11-OH-delta-9-THC 1.87 331.0 n. d. 
4 17-methylmorphinane 1.09 258.4 0.28 
5 2 C-B 1.06 259.9 0.25 
6 2 C-H 0.98 181.9 n. d. 
7 2-OH-desipramine 1.07 283.3 0.41 
8 3-OH-bromazepam 1.15 334.0 n. d. 
9 3-OH-flunitrazepam 1.32 330.0 0.28 
10 4-OH-clobazam 1.25 317.1 0.08 
11 4-OH-clobazam adduct 1.25 333.8 0.12 
12 4-OH-midazolam 1.44 343.1 4.10 
13 6-acetylcodeine 1.03 342.2 n. d. 
14 6-acetylmorphine 0.94 328.2 2.36 
15 7-acetaminoclonazepam 1.11 328.1 2.55 
16 7-aminoclonazepam 1.12 286.2 3.13 
17 7-aminoflunitrazepam 1.17 284.2 n. d. 
18 7-aminonitrazepam 1.00 252.2 4.05 
19 8-OH-amoxapine 1.05 330.0 0.69 
20 9-OH-risperidone 1.04 427.2 3.15 
21 acebutolol 1.00 337.2 2.70 
22 acenocoumarol neg 1.51 352.0 0.38 
23 acetozolamide neg 0.99 221.1 0.02 
24 alimemazine 1.18 299.1 1.17 
25 aloeemodine neg 1.50 270.2 0.29 
26 alpha-OH-alprazolam 1.25 325.2 n. d. 
27 alpha-OH-midazolam 1.23 342.1 3.23 
28 alprazolam 1.32 309.5 8.92 
29 alprenolol 1.10 250.3 0.82 
30 amiloride neg 0.87 211.4 0.00 
31 amiloride 0.88 230.1 0.92 
32 aminophenazone 0.94 232.0 1.92 
33 amiodarone 1.51 646.0 2.56 
34 amisulpiride 0.98 370.1 10.55 
35 amitryptiline 1.17 278.2 4.48 
36 amoxapine 1.12 314.2 2.77 
37 amphetamine 0.96 135.9 n. d. 
38 ampicilline neg 0.93 348.4 0.05 
39 amprenavir 1.42 506.1 7.70 
40 amprenavir adduct neg 1.42 550.0 0.25 
41 apomorphine 0.97 268.2 0.24 
42 aripiprazol 1.17 448.3 4.86 
43 atenolol 0.87 267.2 4.32 
44 atropine 0.99 290.2 n. d. 
45 azacyclonol 1.07 268.0 n. d. 
46 azathioprine 0.99 278.1 n. d. 
47 azosemide neg 1.39 369.4 0.16 
48 BDB 1.00 193.9 n. d. 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
49 bendroflumethiazide neg 1.38 420.1 0.50 
50 benzoylecgonine 1.00 290.2 2.64 
51 benzoylecgonine-d3 1.00 293.2 2.00 
52 benzthiazide adduct 1.33 448.8 0.09 
53 benzthiazide neg 1.34 430.2 0.45 
54 betamethasone 1.69 393.2 0.19 
55 betamethasone adduct 1.68 505.1 3.48 
56 biperidene 1.17 312.2 1.75 
57 bisacodyl 1.54 362.2 0.60 
58 brallobarbital neg 1.24 284.9 0.02 
59 bromadiolone 1.86 510.9 1.02 
60 bromadiolone neg 1.86 525.3 0.14 
61 bromazepam 1.25 318.3 n. d. 
62 brotizolam 1.38 395.0 5.14 
63 buclizine 1.51 433.2 n. d. 
64 buformine 0.69 158.3 0.02 
65 bumetanide 1.42 365.0 0.27 
66 bumetanide neg 1.43 363.2 0.13 
67 bumetanide adduct neg 1.43 408.9 0.36 
68 bupivacaine 1.08 289.2 3.00 
69 buprenorphine 1.13 450.3 4.03 
70 butalbital neg 1.28 223.4 0.02 
71 camazepam 1.57 371.7 n. d. 
72 cannabidiol 2.07 315.1 0.22 
73 cannabinol 2.46 311.1 0.70 
74 canrenone acid 1.28 359.2 0.68 
75 captopril neg 1.08 215.9 0.01 
76 carbamazepine 1.29 237.1 6.33 
77 carbamazepine-10-11-epoxide 1.19 253.0 1.85 
78 carisoprodol 1.36 261.0 n. d. 
79 chlorcyclizine 1.16 300.9 n. d. 
80 chlordiazepoxide 1.18 300.1 3.28 
81 chlorophacinone neg 2.00 373.1 0.31 
82 chloroquine 0.92 320.3 3.56 
83 chlorpheniramine 1.06 275.0 n. d. 
84 chlorpromazine 1.20 319.1 1.27 
85 chlorprothixene 1.23 316.1 3.68 
86 chlorthalidone 1.13 321.2 0.24 
87 cinchocaine 1.15 344.1 11.48 
88 citalopram 1.11 325.2 2.68 
89 clobazam 1.45 301.0 0.13 
90 clomethiazole 1.35 162.1 0.40 
91 clomipramine 1.21 315.1 n. d. 
92 clonazepam 1.37 316.2 2.90 
93 clonidine 0.94 230.2 n. d. 
94 clopenthixol 1.22 401.2 1.50 
95 clorazepate 1.43 271.1 2.53 
96 clotiapine 1.17 344.1 n. d. 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
97 clovoxamine 1.14 285.0 1.08 
98 cloxazolam 1.01 349.1 0.70 
99 clozapine 1.11 327.1 3.93 
100 clozapine-N-oxide 1.11 343.0 n. d. 
101 cocaethylene 1.07 318.2 1.86 
102 cocaine 1.06 304.2 2.26 
103 codeine 0.93 300.3 3.98 
104 codeine-6-glucuronide 0.90 476.2 n. d. 
105 coumachlor 1.62 343.1 1.96 
106 coumachlor neg 1.62 341.1 0.61 
107 coumatetralyl 1.63 293.3 1.24 
108 coumatetralyl neg 1.63 291.2 0.40 
109 crimidine 1.29 172.2 5.08 
110 cyclizine 1.11 267.0 n. d. 
111 cyclopenthiazide neg 1.40 378.2 0.31 
112 cyclothiazide 1.37 390.0 n. d. 
113 cyclothiazide neg 1.36 388.3 n. d. 
114 delorazepam 1.45 305.2 2.52 
115 delorazepam neg 1.44 267.2 0.22 
116 delta-8-THC 2.78 315.1 0.32 
117 delta-9-THC 2.71 315.1 1.86 
118 delta-9-THC d3 2.70 318.3 1.86 
119 demethylcitalopram 1.12 311.1 2.58 
120 demoxepam 1.25 287.1 n. d. 
121 desalkylflurazepam 1.40 289.2 3.32 
122 desalkylremifentanil 1.01 363.0 1.51 
123 desipramine 1.15 267.1 n. d. 
124 desmethylchlorodiazepoxide 1.12 285.9 0.26 
125 desmethylchlorprothixene 1.19 302.1 n. d. 
126 desmethylclobazam 1.35 287.1 0.02 
127 desmethylclobazam adduct 1.35 303.7 n. d. 
128 desmethylclomipramine 1.22 301.1 1.21 
129 desmethylclozapine 1.08 313.4 n. d. 
130 desmethyldiazepam 1.43 271.1 n. d. 
131 desmethyldoxepine 1.12 266.1 n. d. 
132 desmethylflunitrazepam 1.33 300.2 2.86 
133 desmethyllevomepromazine 1.15 301.1 n. d. 
134 desmethyllevomepromazine sulfoxide 1.04 317.3 n. d. 
135 desmethylmaprotiline 1.16 264.1 2.58 
136 desmethylmelitracene 1.21 278.1 3.88 
137 desmethylmianserine 1.11 251.1 n. d. 
138 desmethylmirtazepine 1.01 252.2 1.56 
139 desmethylnortryptiline 1.15 250.3 n. d. 
140 desmethylsertraline 1.18 292.1 n. d. 
141 desmethyltrimipramine 1.18 281.1 1.81 
142 desmethylvenlafaxine 0.98 264.1 3.25 
143 dextrometorphan 1.12 272.2 2.52 
144 diazepam 1.57 285.3 6.26 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
145 diazepambenzophenon 2.03 246.1 1.09 
146 dibenzepine 1.05 296.0 6.67 
147 diclofenac 1.61 296.0 0.82 
148 diclofenac neg 1.61 294.0 0.18 
149 didemethylcitalopram 1.11 297.0 1.50 
150 didemethyltrimipramin 1.15 267.2 1.62 
151 dihydrocodein 0.92 302.3 5.78 
152 dihydrocodeine-6-beta-D-glucuronide 0.89 478.2 n. d. 
153 dihydromorphine 0.62 288.2 2.16 
154 dimethoxyphenethylamine 0.92 181.9 n. d. 
155 dimetindene 1.10 293.1 3.14 
156 diphenhyrdramine 1.12 255.9 1.56 
157 diphenoxylate 1.32 453.3 n. d. 
158 diphylline 0.91 255.1 n. d. 
159 dothiepine 1.16 296.1 4.05 
160 doxepine 1.12 280.4 n. d. 
161 doxycycline 1.07 446.0 0.58 
162 E-10-OH-amitryptiline 1.05 294.1 2.18 
163 E-10-OH-nortryptiline 1.05 280.1 1.03 
164 EDDP 1.15 278.3 3.91 
165 efavirenz neg 1.68 314.3 0.36 
166 emodine neg 1.69 269.5 0.56 
167 enalapril 1.11 377.2 2.07 
168 enalapril neg 1.11 375.5 0.02 
169 ergotamin 1.10 582.0 1.80 
170 ergotamine neg 1.09 580.2 0.06 
171 estazolam 1.31 295.2 5.19 
172 ethacrinic acid neg 1.52 301.2 0.17 
173 ethambutol 0.92 205.1 4.20 
174 ethylmorphine 0.96 314.2 n. d. 
175 fentanyl 1.12 337.5 5.27 
176 flunitrazepam 1.42 314.1 3.47 
177 fluorescein 1.33 333.3 n. d. 
178 fluorescein neg 1.32 331.3 n. d. 
179 fluoxetine 1.18 309.9 n. d. 
180 flupenthixol 1.17 435.2 3.94 
181 fluphenazine 1.22 438.2 n. d. 
182 flurazepam 1.11 388.1 5.13 
183 fluvoxamine 1.16 319.0 1.54 
184 furosemide neg 1.30 329.0 0.25 
185 glafenine 1.00 373.1 3.16 
186 glafenine neg 1.00 371.0 0.06 
187 glafenic acid 1.05 299.1 0.88 
188 glafenic acid neg 1.06 297.0 0.03 
189 glibenclamid neg 1.56 492.3 0.55 
190 glibenclamide 1.56 494.0 0.30 
191 glibornuride 1.53 367.1 0.14 
192 glibornuride neg 1.53 365.0 0.14 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
193 gliclazide 1.52 324.2 0.12 
194 gliclazide neg 1.52 322.2 0.08 
195 haloperidol 1.15 376.1 3.53 
196 heptabarbital 1.32 251.0 0.32 
197 heroine 1.02 370.3 n. d. 
198 hexobarbital 1.35 236.9 0.01 
199 HMA 0.88 181.9 n. d. 
200 HMMA 0.89 196.2 n. d. 
201 hordenine 0.63 166.0 0.12 
202 hydrochlorothiazide neg 1.08 296.5 0.01 
203 hydrocodone 0.98 300.6 5.46 
204 hydrocortisone adduct neg 1.20 407.1 0.19 
205 hydroflumethiazide neg 1.15 330.3 0.08 
206 hydroflumethiazide adduct neg 1.15 375.9 0.06 
207 hydromorphine 0.88 286.2 n. d. 
208 hydromorphone 0.88 286.4 2.88 
209 hydroxy imipramine 1.08 297.2 0.62 
210 hydroxy levomepromazine 1.10 345.2 0.45 
211 hydroxyphenamate 1.20 191.9 n. d. 
212 imipramine 1.16 281.2 1.62 
213 indinavir 1.09 614.3 13.94 
214 indinavir adduct neg 1.09 658.4 0.75 
215 isocarboxazide 1.24 232.1 n. d. 
216 isoniazide 0.58 138.1 0.05 
217 ketamine 0.99 238.0 3.79 
218 labetolol 1.06 329.0 n. d. 
219 lamotrigine 1.02 256.2 0.33 
220 l-ephedrine 0.93 166.3 2.38 
221 levallorphan 1.04 284.2 n. d. 
222 levomepromazine 1.12 329.1 1.28 
223 levomepromazine sulfoxide 1.06 345.2 2.35 
224 levorphanol 1.00 258.4 0.40 
225 lidocaine 1.00 235.1 2.40 
226 lobeline 1.14 338.2 n. d. 
227 lofepramin 1.38 419.1 2.06 
228 lopinavir 1.58 629.1 6.08 
229 lopinavir adduct neg 1.58 673.0 1.66 
230 lorazepam neg 1.35 319.0 0.15 
231 lorazepam 1.35 321.2 3.00 
232 lormetazepam 1.47 335.0 1.53 
233 lormetazepam neg 1.46 298.0 0.25 
234 LSD 1.07 324.3 2.34 
235 maprotiline 1.17 278.1 3.83 
236 MBDB 1.00 208.0 n. d. 
237 MDA 0.97 179.9 n. d. 
238 MDEA 1.00 207.9 5.92 
239 MDMA 0.99 194.0 n. d. 
240 mebeverine 1.16 430.2 2.48 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
241 meclizine 1.35 391.1 n. d. 
242 medazepam 1.18 271.2 n. d. 
243 mefenamic acid neg 1.74 240.2 6.10 
244 mefenamic acid 1.74 242.2 n. d. 
245 melitracene 1.22 292.2 1.39 
246 mephenoxalone adduct 1.17 240.9 1.37 
247 mephentermin 0.99 164.0 n. d. 
248 mepivacaine 0.99 247.1 2.34 
249 meprobamate 1.15 218.9 n. d. 
250 mescaline 0.94 211.9 8.24 
251 mesoridazine 1.09 387.1 3.26 
252 metalazone 1.29 366.0 2.60 
253 metalazone neg 1.28 364.5 n. d. 
254 metamphetamine 0.98 150.0 n. d. 
255 methadone 1.21 310.3 n. d. 
256 methapyrilene 1.06 262.0 n. d. 
257 methaqualone 1.43 251.2 n. d. 
258 methocarbamol 1.11 242.0 5.84 
259 methohexital 1.50 263.0 n. d. 
260 metixene 1.20 310.4 3.04 
261 metoclopramide 1.00 300.1 0.04 
262 metoprolol 1.01 268.2 0.01 
263 metronidazolum 0.98 172.1 3.34 
264 mianserine 1.11 265.2 0.14 
265 mianserine-N-oxide 1.14 281.1 4.54 
266 midazolam 1.15 326.2 0.70 
267 minoxidil 0.99 210.1 6.04 
268 mirtazapine 1.01 266.1 1.23 
269 moclobemide 1.00 269.1 16.86 
270 morphine 0.78 286.2 3.29 
271 morphine-6-glucuronide 0.82 462.1 n. d. 
272 MPPH 1.36 267.1 0.02 
273 N1-OH-ethylflurazepam 1.35 333.1 1.72 
274 nadolol 0.94 310.2 4.86 
275 nalbuphine 0.97 358.3 n. d. 
276 nalorphine 0.91 312.2 2.50 
277 naloxone 0.92 328.1 12.00 
278 naltrexone 0.94 342.1 n. d. 
279 naltrexone neg 0.93 341.5 4.32 
280 N-desmethylclozapine 1.08 313.4 5.62 
281 nelfinavir 1.23 568.5 0.04 
282 nelfinavir adduct neg 1.23 612.2 n. d. 
283 N-ethyloxazepam 1.52 315.0 n. d. 
284 nevirapine 1.16 267.3 0.08 
285 nifedipine adduct neg 1.47 391.3 0.26 
286 nifedipine neg 1.47 345.1 2.95 
287 nifedipin metabolite 1.47 329.0 1.30 
288 nitrazepam 1.35 282.1 10.51 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
289 nomifensine 1.06 239.1 2.44 
290 norcodeine 0.92 286.3 0.15 
291 norfentanyl 0.99 233.0 0.05 
292 normorphine 0.77 272.1 2.22 
293 nortryptiline 1.17 362.3 0.33 
294 noscapine 1.10 414.1 2.56 
295 noxiptiline 1.16 295.0 5.27 
296 nylindrine 1.07 300.1 5.81 
297 ofloxacine 0.96 362.3 0.09 
298 olanzapine 0.93 313.2 3.80 
299 opipramol 1.11 364.2 1.24 
300 oxazepam 1.33 287.1 7.20 
301 oxcarbazepine 1.22 253.0 1.78 
302 oxprenolol 1.06 266.2 0.72 
303 oxycodone 0.96 316.1 n. d. 
304 oxymetazoline 1.10 261.2 2.84 
305 oxymorphone 0.82 302.1 n. d. 
306 papaverine 1.06 340.5 4.18 
307 paracetamol 0.95 152.1 2.12 
308 paroxetine 1.14 330.1 8.34 
309 PCP 1.10 243.9 4.10 
310 penfluridol 1.35 524.7 2.84 
311 pentazocine 1.07 286.1 0.57 
312 perazine 1.18 340.2 n. d. 
313 periciazine 1.12 366.1 3.31 
314 perphenazine 1.18 404.3 6.26 
315 pethidine 1.05 248.1 1.16 
316 phenacetin 1.23 180.2 2.66 
317 phenazopyridine 1.21 214.2 0.89 
318 phendimetrazine 0.96 192.1 0.80 
319 phenindamine 1.13 262.1 n. d. 
320 pheniramine 0.99 241.0 0.28 
321 phenobarbital neg 1.23 231.2 0.25 
322 phenolphthalein 1.32 319.1 n. d. 
323 phenprocoumon 1.60 281.1 0.41 
324 phenprocoumon neg 1.60 279.1 n. d. 
325 phenylbutazone neg 1.68 307.5 0.28 
326 pholcodine 0.60 399.2 0.08 
327 pimozide 1.22 462.2 0.12 
328 pinazepam 1.62 309.3 4.10 
329 pindolol 0.98 249.2 n. d. 
330 PMA 0.97 165.9 2.36 
331 PMMA 0.99 179.9 2.55 
332 prazepam 1.75 325.1 3.13 
333 procaine 0.92 237.0 n. d. 
334 promazine 1.16 285.0 4.05 
335 promethazine 1.15 285.0 0.69 
336 propoxyphene 1.18 339.9 3.15 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
337 propranolol 1.09 260.2 2.70 
338 propylhexedrine 1.05 156.1 0.38 
339 propyphenazone 1.40 231.2 0.02 
340 protryptiline 1.15 264.1 1.17 
341 pseudoephedrine 0.93 166.3 0.29 
342 psilocyn 0.91 205.0 n. d. 
343 pyrilamine 1.08 286.0 3.23 
344 pyrrobutamine 1.20 312.1 8.92 
345 quazepam 1.79 387.1 0.82 
346 quazepam neg 1.79 384.9 0.00 
347 quetiapine 1.10 384.3 0.92 
348 quinine 0.99 325.2 1.92 
349 ranitidine 0.88 315.1 2.56 
350 ranitidine adduct neg 0.88 358.7 10.55 
351 ranitidine neg 0.88 313.1 4.48 
352 remifentanil 1.04 377.2 2.77 
353 rhein neg 1.49 283.1 n. d. 
354 risperidone 1.05 411.0 0.05 
355 ritalinic acid 0.98 220.3 7.70 
356 ritonavir 1.54 721.1 0.25 
357 ropivacaine 1.06 275.1 0.24 
358 saquinavir 1.18 671.3 4.86 
359 saquinavir adduct neg 1.18 715.1 4.32 
360 scopolamine 0.96 304.1 n. d. 
361 secobarbital neg 1.37 237.1 n. d. 
362 sertraline 1.19 306.1 n. d. 
363 sotalol 0.90 273.0 0.16 
364 strychnine 0.97 335.3 n. d. 
365 sulforidazine 1.12 403.2 0.50 
366 sulpiride 0.90 342.2 2.64 
367 tadalafil 1.34 390.1 2.00 
368 temazepam 1.45 301.0 0.09 
369 tetrazepam 1.72 289.2 0.45 
370 thalidomide neg 1.19 258.3 0.19 
371 thebaine 1.04 312.4 3.48 
372 thenyldiamine 1.06 262.0 1.75 
373 theophylline neg 0.93 179.2 0.60 
374 thiabutizide neg 1.33 352.4 0.02 
375 thioproperazine 1.16 447.2 1.02 
376 thioridazine 1.18 371.5 0.14 
377 tiapride 0.93 329.1 n. d. 
378 timolol 1.00 317.1 5.14 
379 tolbutamide neg 1.42 269.2 n. d. 
380 torasemide neg 1.14 347.3 0.02 
381 torasemide 1.14 349.0 0.27 
382 tramadol 1.02 264.0 0.13 
383 trazodone 1.08 372.2 0.36 
384 triamterene 0.97 254.3 3.00 
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Table VII (continued). Relative Retention Times (RRT), Molecular Ions, and Area Ratios 
(Area Compound / Area Internal Standard) of the Screened Compounds. 
 Compound RRT Molecular Ion  Area Ratio 
385 triazolam 1.34 343.2 4.03 
386 trichlormethiazide neg 1.25 379.7 0.02 
387 trifluperidol 1.17 410.1 n. d. 
388 triflupromazine 1.24 353.1 0.22 
389 trimethoprim 0.96 291.1 0.70 
390 trimipramine 1.18 295.2 0.68 
391 trimipramine metabolite 1 1.20 250.3 0.01 
392 tripelenamine 1.07 256.0 6.33 
393 tubocurarine 0.94 609.3 1.85 
394 tybamate 1.44 274.9 n. d. 
395 vardenafil 1.07 489.3 n. d. 
396 venlaflaxine 1.02 278.2 3.28 
397 verapamil 1.16 455.3 0.31 
398 voriconazole 1.36 350.0 3.56 
399 warfarin 1.53 309.1 n. d. 
400 warfarin neg 1.53 307.2 1.27 
401 xylometazoline 1.15 245.2 3.68 
402 Z-10-OH-amitryptiline 1.09 294.1 0.24 
403 zolpidem 1.06 308.2 11.48 
404 zopiclone 1.00 389.0 2.68 
405 zuclopenthixol 1.14 401.2 0.13 
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5.2.6. Comparison of LC-MS and HPLC-DAD 
The LC-MS GUS procedure in the positive mode was compared with the same 
procedure in the negative mode and the HPLC-DAD analysis for 100 substances. On-
line solid-phase extraction procedure on Hysphere GP resin cartridges was used for 
LC-MS and off-line SPE on Oasis HLB cartridges was used for HPLC-DAD. 
 
It was found that LC-MS in the positive mode was able to detect 73 out of 100 
compounds, versus 28% for LC-MS in the negative mode and 61% for HPLC-DAD. 
29% of all the compounds were only detected by LC-MS in the positive mode, versus 
6% in the negative mode and 13% for HPLC-DAD (Fig. 12). These results showed the 
efficiency of LC-MS in both modes in combination with HPLC-DAD as a screening 
procedure in toxicology. 
 
MS-MS in toxicology brings higher specificity and selectivity and more structural 
information to explore an unknown chromatographic peak. For the most drugs or toxic 
compounds, the LOD was lower with the LC-MS than with the HPLC-DAD 
procedure. 
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Fig. 12. Comparison of LC-MS in a positive mode, LC-MS in a negative mode and HPLC-
DAD general unknown screening procedure for the detection of 100 substances at a low toxic 
concentration. 
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5.3. CASE REPORTS 
The DDA LC-MS-MS system has been applied to several cases. The following 
examples illustrate the application of the system for clinical investigations. The results 
of urine and serum samples analysis using SPE-LC-MS-MS were compared to the 
results obtained with a conventional GUS technique (including immunoassay, REMEDi 
and LC-MS). REMEDi (Biorad) is an HPLC-based broad-spectrum drug profiling 
system. It is used to detect and identify drugs in clinical serum and urine samples. The 
REMEDi is designed to identify basic and neutral drugs and their metabolites. The 
system can also be used for the identification of benzodiazepines. These systems were 
applied in the present laboratory for several years. 
 
Seventeen urine and twentyfive serum samples of potentially intoxicated individuals 
and drug addicts were analyzed (Table VIII, IX).  
Urine samples were treated like serum samples and were analyzed with both systems. 
The LC-MS-MS system found in addition to the REMEDi 7-aminoflunitrazepam (case 
5), mirtazapine (case 8), zolpidem (case 8 and 10), metoprolol (case 8), phenprocoumon 
(case 10), ephedrine, mephentermine, lidocaine (all in case 11), torasemide, 
propylhexedrine (both in case 12) and 3-OH-bromazepam (case 14). The LC-MS-MS 
procedure failed to detect diphenhydramine, the metabolite of diphenhydramine (both in 
case 5), heroin, 6-acetylmorphine (case 5 and 10), hydrocodone (case 10), phenobarbital 
(case 12), a metabolite of chlorprothixene (case 13), quinine (case 14), 7-OH-quetapine 
and N-OH-ethylflurazepam (case 16). 
 
A number of drugs in serum have been detected by the DDA approach, which were not 
found by the REMEDi system including metoclopramide (case 19), amisulpiride, 
atenolol (both case 25), mefenamic acid (case 27 and 37), codeine-6-glucuronide (38) 
and lamotrigine (case 27). On the other hand atracurium (case 19), dipyrone (case 19 
and 34), citalopram (case 25 and 31), venlafaxine and its metabolite, tramadol (both 
case 27), fluconazole, bisoprolol (both case 40) and acetaminophen (case 19 and 38) 
were missed by the new developed system. 
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Table VIII. Comparison of DDA LC-MS-MS Procedure to Conventional GUS Technique 
(Immunoassay and REMEDi) of Urine Samples. 
No. 
 
Immunoassay REMEDi DDA LC-MS-MS Comment/LC-MS 
Confirmation 
1   Lidocaine Only Benzodiazepine 
REMEDi 
 Cocaine  Cocaine, Benzoylecgonine Cocaine, Benzoylecgonine 
 Methadone, 
EDDP 
 Methadone, EDDP  
 Benzodiazepine Temazepam, 
Desmethyldiazepam 
Oxazepam, Oxazepam-
glucuronide, Temazepam, 
Temazepamglucuronide, 
Desmethyldiazepam 
 
 Cannabis    
2 Opiate Normorphine, 
Morphine, Codeine-
6-glucuronide, 
Norcodeine 
Normorphine, Morphine, 
Codeine-6-glucuronide, 
Codeine, Norcodeine 
Morphine, Morphine-
glucuronides, Codeine-6-
glucuronide, Codeine, 
Norcodeine 
3 Opiate Morphine, Codein-
6-glucuronide, 
Codeine 
Normorphine, Codeine-6-
glucuronide, Morphine-
glucuronide, Codeine 
 
  Atenolol Atenolol  
4 Cocaine Cocaine, Benzoyl-
ecgonine 
Cocaine, Benzoylecgonine, 
Cocaethylene 
Alcohol 
  Mepivacaine Mepivacaine  
5 Opiate,  
6-Acetyl-
morphine 
Morphine, 
Morphine-
glucuronide 
Morphine, 
Morphineglucuronide 
Morphine, Morphine-
glucuronide, Heroin, 6-
Acetylmorphine 
  Trimipramine Hydroxyimipramine, 
Trimipramine 
No immunoassay  
 Benzodiazepine Desmethyldia-
zepam, Temazepam, 
Oxazepam,  
Desmethyldiazepam, 
Temazepam, 
Temazepamglucuronide, 
Oxazepamglucuronide, 7-
Aminoflunitrazepam, 
 
  Diphenhydramine, 
Metabolite of 
Diphenhydramine, 
  
 Methaqualone  Methaqualone  
 Cannabis    
6 Methadone, 
EDDP 
Methadone, EDDP EDDP  
 Opiate Hydrocodone, 
Dihydromorphine, 
Hydromorphone,  
Hydrocodone, Dihydro-
codeine, Dihydrocodeine-6-
glucuronide, Norcodeine,  
Hydrocodone, Dihydro-
codeine, Morphine-
glucuronide 
 Benzodiazepine Desmethyldia-
zepam, Temazepam 
Desmethyldiazepam, 
Temazepamglucuronide, 
Oxazepam, Oxazepam-
glucuronide 
 
 Cannabis  11-nor-delta-THC-COOH  
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Table VIII (continued). Comparison of DDA LC-MS-MS Procedure to Conventional GUS 
Technique (Immunoassay and REMEDi) of Urine Samples. 
No. 
 
Immunoassay REMEDi DDA LC-MS-MS Comment/LC-MS 
Confirmation 
7  Desmethylmirtazapine Mirtazapine, 
Desmethylmirtazapine 
No immunoassay 
8  Venlafaxine, 
Desmethylvenlafaxine 
Venlafaxine, 
Desmethylvenlafaxine 
 
 Benzodiazepine Oxazepam Oxazepam, Oxazepam-
glucuronide,  
 
   Mirtazapine  
   Zolpidem  
   Metoprolol  
9 Antidepressant Amitryptiline, 
Nortryptiline 
Nortryptiline, E-10-OH-
Nortryptiline 
 
 Benzodiazepine  Bromazepam, 3-OH-
Bromazepam 
 
10 Opiate Dihydrocodeine, 
Hydrocodone, Meta-
bolite of Hydrocodone 
Normorphine, 
Dihydrocodeine-
glucuronide 
Morphine, Dihydroco-
deine, Heroin, 6-Acetyl-
morphine, Hydrocodone 
   Zolpidem  
  Alpha-OH-Midazolam 4-OH-Midazolam  
   Phenprocoumon  
 Cocaine   Cocaine, Benzoylecgonine 
11 Amphetamine MDMA Ephedrine, MDMA, 
Mephentermine 
Ephedrine, MDMA, MDA, 
Amphetamine, 
Metamphetamine 
 Cocaine Benzoylecgonine Benzoylecgonine  
 Benzodiazepine    
  Methadone, EDDP EDDP  
   Lidocaine  
12 Methadone, 
EDDP 
Methadone, EDDP EDDP  
 Barbiturate 
(Phenobarbital) 
   
   Torasemide  
   Propylhexedrine  
13 Methadone, 
EDDP 
Methadone, EDDP Methadone, EDDP  
  Metabolite of 
chlorprothixene 
 Not in the library 
 Cannabis    
14 Amphetamine MDMA, MDA MDMA Immunoassay only 
Amphetamine 
  Cocaine, Benzoyl-
ecgonine 
Benzoylecgonine  
  Desethylflurazepam, 
Didesethylflurazepam 
Flurazepam, N-OH-
Ethylflurazepam, 3-OH-
Bromazepam 
Desethylflurazepam and 
Didesethylflurazepam not 
in the library 
  Quinine   
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Table VIII (continued). Comparison of DDA LC-MS-MS Procedure to Conventional GUS 
Technique (Immunoassay and REMEDi) of Urine Samples. 
No. 
 
Immunoassay Remedi  DDA LC-MS-MS Comment/LC-MS 
Confirmation 
15 Cocaine  Benzoylecgonine Cocaine, Benzoylecgonine 
 Benzodiazepine Temazepam, 
Desmethyldiazepam 
Oxazepam, Temazepam, 
Temazepamglucuronide 
 
 Opiate    
 (Amphetamine)   Amphetamine negative 
 Cannabis    
16  Olanzapine,  Olanzapine  
  7-OH-Quetiapine  7-OH-Quetiapine not in 
library 
 Amphetamine MDA, MDMA MDA, MDMA, MDEA MDA, MDMA, MDEA 
 Benzodiazepine N-OH-Ethyl-
flurazepam 
  
  Carbamazepine Carbamazepine  
17 n. d.  n. d. n. d. Ibuprofen and its metabolites 
(by HPLC-DAD) 
 
Atracurium, dipyrone, fluconazole, bisoprolol, a metabolite of chlorprothixene and 7-
OH-quetiapine were not detected because MS data of these substances were not 
recorded and included into the library. Venlafaxine, citalopram, tramadol, 
acetaminophen, diphenhydramine and quinine were not detected probably due to a 
higher LOD of the LC-MS-MS system. That means that the concentrations were in 
therapeutic concentrations and not in the toxic range. Heroin, 6-acetylmorphine and 
hydrocodone were also missed due to higher LOD of the DDA approach. Salicylate and 
phenobarbital were detected neither with the REMEDi system nor with the LC-MS-MS 
procedure. Other acidic substances like mefenamic acid, torasemide were identified 
only with the DDA method. Acidic substances can be detected with the presented 
HPLC-DAD method (see 4.1.). A typical HPLC-DAD chromatogram of mefenamic 
acid with its metabolites is shown (Fig. 13, case 37). Case 17 was a suspected 
intoxication with ibuprofen. Ibuprofen and its metabolites were only detected by the 
HPLC system. 
 
The cut-off for the immunoassay test of cannabinoids is lower (50 ng/mL) than the 
LOD detected with the DDA approach. In cases (1, 5, 15) the concentrations of the 11-
nor-delta-THC-COOH were above the cut-off of the immunoassay and below the LOD 
of the DDA approach, the substance was only identified by immunoassay. In higher 
concentrations (above the LOD) 11-nor-delta-THC-COOH was also detected by the 
LC-MS-MS system (in case 6). 
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In general the same substances were detected with both systems. With the developed 
LC-MS-MS system basic, neutral as well as acidic substances can be identified in the 
same run. The REMEDi is designed to identify basic and neutral drugs and their 
metabolites. Acidic substances like mefenamic acid cannot be detected with this system, 
benzodiazepines are analysed in a special second run (with other equipment). This is 
one of the major advantages of the DDA approach. Other advantages are that the 
analysis time is much shorter and the hydrolysis of glucuronides is not necessary. In 
addition samples often have to be diluted with the REMEDi system up to 3 - 5 times 
depending on the concentration of the substance. 
 
 
Fig. 13. Chromatogram of mefenamic acid and its metbolites of a serum sample (case 
37). 
 
The presented method is robust and the information content is high. Substances from 
different groups (amphetamines, antidepressants, benzodiazepines, cannabinoids, 
cocaine, opiates, antidepressant, diuretics, antidiabetics, opiates, neuroleptics, 
analgesics etc.) were detected and identified. 
 
Mefenamic acid 
glucuronides 
Hydroxymethylmefenamic acid 
and carboxymefenamic acid 
Mefenamic acid 
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Table IX. Comparison of DDA LC-MS-MS Procedure to Conventional GUS Technique 
(Immunoassay and REMEDi) of Serum Samples. 
No. 
 
Immunoassay REMEDi DDA LC-MS-MS Comment/LC-MS 
Confirmation 
18 Benzodiazepine  Oxazepam, Oxazepam-
glucuronide 
No benzodiazepine 
REMEDi 
  Moclobemide Moclobemide  
19 Benzodiazepine  Oxazepam, Oxazepam-
glucuronide 
No benzodiazepine 
REMEDi 
  Ranitidine Ranitidine  
  Lidocaine, Meta-
bolite of Lidocaine 
Lidocaine  
  Atracurium  Not in the LC-MS-MS 
library 
  Dipyrone  Not in the LC-MS-MS 
library 
   Metoclopramide  
 Acetaminophen    
20 Methadone Methadone Methadone  
 Benzodiazepine  Temazepam, Oxazepam, 
Diazepam, Desmethyl-
diazepam 
No benzodiazepine 
REMEDi 
   Carbamazepine, 10,11-
dihydro-10-OH-Carbama-
zepine, Oxcarbamazepine 
 
21 Opiate n. d. n. d.  
 Alcohol    
22 Benzodiazepine  Oxazepam, Oxazepam-
glucuronide, Desmethyl-
diazepam 
No benzodiazepine 
REMEDi 
  Metoclopramide Metoclopramide  
23 n. d.  n. d. n. d.  
24 Antidepressants Desmethyltrimi-
pramine 
Trimipramine, Desmethyl-
trimipramine 
 
 Methadone Methadone Methadone  
 Benzodiazepine  Diazepam, 
Desmethyldiazepam 
No benzodiazepine 
REMEDi 
25 n. d. Citalopram  Not found because of 
interference with clozapine 
  Clozapine, 
Metabolite of 
Clozapine 
Clozapine, N-Desmethyl-
clozapine, Clozapine-N-
Oxide 
 
   Amisulpiride  
   Atenolol  
26 Benzodiazepine n. d. Oxazepam, Oxazepam-
lucuronide 
No benzodiazepine 
REMEDi 
   Gliclazide  
 
Results and Discussion 
82 
 
Table IX (continued). Comparison of DDA LC-MS-MS Procedure to Conventional GUS 
Technique (Immunoassay and REMEDi) of Serum Samples. 
No. 
 
Immunoassay REMEDi DDA LC-MS-MS Comment/LC-MS 
Confirmation 
27 Benzodiazepine  Lorazepam, N-OH-Ethyl-
flurazepam, Desalkyl-
flurazepam, Diazepam 
No benzodiazepine 
REMEDi 
  Sulpiride Sulpiride  
  Venlafaxine   
  Metabolite of 
Venlafaxine 
  
  Tramadol   
   Lamotrigine  
28 n. d.  n. d. n. d.  
29 n. d.  n. d. n. d.  
30 Alcohol    
 Cananbis    
  Fluoxetine, Meta-
bolite of Fluoxetine 
Fluoxetine  
31 n. d. Citalopram   
  Ephedrine?   
   Mefenamic acid  
32 Cocaine Cocaine, Benzoyl-
ecgonine 
Benzoylecgonine  
33 Benzodiazepine  Lorazepam  
34 Opiate Pethidine, Meta-
bolite of Pethidine 
Pethidine Metabolite not in the LC-
MS-MS library 
 Benzodiazepine  Diazepam No benzodiazepine 
REMEDi 
  Dipyrone   
35 Antidepressant Amitryptiline Amitryptiline, E-10-
Amitryptiline, Nortryptiline 
 
  Zolpidem Zolpidem  
 Salicylate   Ibuprofen and its meta-
bolites (by HPLC-DAD) 
36 n. d.  n. d. n. d.  
37 n. d.  n. d. Mefenamic acid Mefenamic acid and its 
metabolites (by HPLC-
DAD) 
38 Opiate  Codeine-6-glucuronide  
 Cocaine Cocaine, Benzoyl-
ecgonine 
Benzoylecgonine  
 Acetaminophen    
39 n. d.  n. d. n. d.  
40 n.d.  Fluconazole n.d.  Not in the LC-MS-MS 
library 
  Bisoprolol  Not in the LC-MS-MS 
library 
41 n. d. Quetiapine, 7-OH-
Quetiapine 
Quetiapine Metabolite not in the LC-
MS-MS library 
   Lamotrigine  
42 n. d.  n. d. n. d.  
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5.4. CONCLUSION 
In conclusion, for routine screening the combination of SPE, LC and APCI-MS 
represents an attractive alternative to the well-established technique of GC-MS. It was 
demonstrated in this study that the SPE-APCI-MS screening method is suitable for 
routine measurements of serum samples. The described procedure is fully automated 
(from the extraction to the detection of a drug) and easy to handle. The method is highly 
specific because compounds are detected and identified by their retention times, their 
molecular ions and fragments. Rapid identification in screening experiments was 
achieved by the creation of a small application program. With the method presented 
here, the analysis of a serum sample can be performed in less than one hour. The 
constructed library comprises more than 400 spectra with the corresponding relative 
retention times of more than 350 compounds. 
 
Out of 100 tested compounds, only 13 were not detectable with this LC-MS method. 
These compounds have high serum concentrations and can easily be detected with 
HPLC-DAD. HPLC-DAD together with the described method seems to be an ideal 
combination for a GUS. 
 
It was demonstrated that the DDA-mediated-LC-MS-MS screening approach was a 
valuable alternative to the traditional GUS procedure for the analysis of samples from 
potentially intoxicated individuals and drug addicts. Almost all of the drugs detected by 
the conventional techniques as well as additional drugs were identified. 
 
The future approach will address the robustness of the method by analysing high 
numbers of samples from potentially poisoned patients and comparing to conventional 
screening methods. Furthermore, the quantification method of detected substances has 
to be established. It will also be of interest to expand the LC-MS-MS library. 
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6. APPENDIX 
6.1. PROPOFOL 
6.1.1. Introduction 
Propofol (2,6-diisopropylphenol, I.C.I. 35868) is a rapid-acting, intravenously 
administered anaesthetic agent for the induction and maintenance of general 
anaesthesia (67). 
For use in a clinical study (68), a fast and sensitive method was developed to 
determine propofol in human serum. Expected serum concentrations after propofol 
infusion were compared to real serum concentrations. 
6.1.2. Materials and Methods 
6.1.2.1. Reagents and Chemicals 
Propofol and trimethylammonium chloride were obtained from Sigma-Aldrich 
Steinheim, Germany). All solvents and buffer solutions in HPLC grade were 
purchased from Merck (Darmstadt, Germany). Solid-phase extractions (SPE) were 
carried out on Oasis MCX cartridges (Waters, Rupperswil, Switzerland). Deionised 
water was prepared on a MilliQ Purification System. 
6.1.2.2. Apparatus and Instrumental Conditions 
A Varian Pro Star HPLC system was used for this analysis. It consisted of a Pro Star 
230 solvent delivery module (SDM), a Pro Star 330 PDA Detector, and a Star 
chromatography workstation system with software version 5.50. The analytical 
column used was an Spheri-5, RP-8 (5 µm, 220 x 4.6 mm) protected by an Spheri-5, 
RP-8 (5 µm, 30 x 4.6 mm) both obtained from Perkin Elmer. 
The HPLC was used in the isocratic mode with an aqueous mobile phase of 0.02 
mol/L KH2PO4 buffer (pH 3.5) / acetonitrile (40:60, v/v) at a flow rate of 1.2 
mL/min. The photodiode array (PDA) detector was set at a detection wavelength of 
220 nm, and the injection volume was 150 µL in a loop of 20 µL. The approved 
method resulted in a retention time of 9.9 min for propofol and an overall running 
time of 15 min. 
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6.1.2.3. Standard Preparation 
A stock solution of propofol (100 mg/mL) was prepared in acetonitrile/water (20:80, 
v/v). The working standards were made from the stock by appropriate dilutions with 
deionised water. The solutions were added to lyophilized drug free serum (Biorad, 
Reinach, Switzerland) yielding concentrations ranging from 0.1 to 10 mg/L. 
6.1.2.4. Extraction Procedure 
The solid-phase extraction (SPE) procedure was carried out on Oasis MCX 
cartridges. The Oasis MCX cartridges were conditioned initially with acetonitrile 
1ml, followed by 1 ml 0.1 mol/L phosphate buffer (pH 9.1). 1 mL per serum sample 
was loaded onto the cartridges. Cartridges were subsequently washed with 1 mL 0.1 
mol/L phosphate buffer (pH 9.1) and dripped dry under charging pressure. The 
compound of interest was eluted with 1 mL acetonitrile and aliquots were injected 
into the HPLC columns. 
6.1.3. Results and Discussion 
The absolute recoveries of propofol in serum were determined by quantitating the 
measured amount over the range of 0.1-20 mg/L compared to primary standards 
directly made up in acetonitrile/water (Table X). The absolute recovery was between 
91 and 116%. This absolute recovery illustrates good extraction efficiency. 
 
 Table X. Absolute Recoveries of Propofol in Serum Compared to Propofol 
Standards in Acetonitrile/Water. 
Absolute recovery in serum 
(%) 
 Range studied 
(mg/L) 
Mean CV 
 0.1 100 16.3 
 1 101 3.9 
 5 116 7.5 
 10 92 5.8 
 20 91 3.5 
 
The limit of quantification of the procedure was found to be 0.1 mg/L based on the 
signal to noise response and the standard deviation of samples in serum. The procedure 
showed good linearity between the concentrations of 0.1 and 10 mg/L with a correlation 
coefficient of 0.997. 
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On eight different days 2 samples were quantified of each concentration. Intraassay 
coefficients of variation (CV) at the concentrations of 0.1, 1.0 and 10 mg/L were 11.6%, 
2.8% and 3.0%, respectively. Interassay CV at the concentration of 0.1, 1.0 and 10 
mg/L were 16.0%, 9.2% and 4.4% (Table XI), respectively. 
 
 
Table XI. Validation Data for Propofol. 
Coefficients of variation (%)  Concentration 
(mg/L) Intraassay Interassay 
 0.1 11.6 16.0 
 1 2.8 9.2 
 10 3.0 4.4 
 
For a clinical study (GLP certified) propofol concentrations were measured in serum 
samples of 9 different individuals. Fig. 14 shows the serum concentration-time curves 
of propofol after intravenous administration of propofol. With an automated system 
propofol was individually administered to the subjects according to a fix dosis scheme. 
From 45 to 105 minutes the serum concentration was expected to be at 1 mg/L, from 
120 to 180 minutes at 2 mg/L, and finally from 195 to 255 minutes at 3 mg/L. At each 
time point serum was taken and analysed. 
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Fig. 14. Serum concentration-time curves of propofol after intravenous administration 
of propofol to 9 individuals (P01-P09). From 45 to 105 minutes the propofol serum 
concentration was expected to be at 1 mg/L, from 120 to 180 minutes at 2 mg/L and 
from 195 to 255 minutes at 3 mg/L. 
 
Expected serum concentrations after propofol infusion were compared to real serum 
concentrations. The measured serum concentrations matched well with the expected 
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serum concentrations (Table XII). The difference of the average of the 9 individuals 
between the measured and the expected propofol serum concentrations were less than 
15% at each time point. 
 
 Table XII. Average of Propofol Serum Concentrations of Nine Individuals 
after Infusion. Difference between the Expected and the Measured Serum 
Concentrations. 
 Measured serum concentration 
mg/L 
 
Time 
(min) 
Expected 
serum 
concentration 
mg/L 
Mean S.D. 
Difference (%) 
between 
measured and 
expected 
concentration 
 45 1 0.95 0.29 -5 
 105 1 0.85 0.21 -15 
 120 2 2.15 0.44 +8 
 180 2 2.09 0.60 +5 
 195 3 3.36 0.39 +12 
 255 3 3.38 0.62 +13 
 
The method proved to be reproducible, accurate, simple and useful in clinical 
investigation and in monitoring propofol concentrations. The aimed serum 
concentrations of propofol in the clinical study were achieved with less than 15% 
difference at each time point. 
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6.2. REMIFENTANIL 
6.2.1. Introduction 
Remifentanil is an ultra-short-acting opioid anaesthetic agent. It is extensively used for 
short-term anaesthesia, often in combination with sedatives. The compound has a N-
substituted labile methyl ester which is highly susceptible to chemical and enzymatic 
hydrolysis resulting in a short half-life of remifentanil (69). It has an elimination half-
life in vivo of 3-10 min, which is much shorter than those of fentanyl, sufentanil and 
alfentanil. The addition of citric acid lowers the pH sufficiently to prevent forms of 
hydrolysis, allowing blood samples to be safely stored for at least 20 h at room 
temperature, frozen for at least a year (70). 
To date, bioanalytical literature for the chromatography of remifentanil has described 
a GC-MS method (71), a GC method with nitrogen-specific detection (70), 2 HPLC 
methods with UV detection (69, 72) and a LC-MS-MS method (73). The HPLC are 
simpler and less expensive, but have limited sensitive. They were not appropriate for 
our pharmacokinetic study. The described GC-MS methods require a time consuming 
sample preparation and analytical procedure. As extraction procedure all the methods 
used a LLE (69, 72). The combination of sensitivity, specificity and high sample 
throughput were the main reasons to use LC-MS-MS with SPE.  
For use in a clinical study (68), a fast and sensitive assay method was developed using 
a SPE to determine remifentanil in human whole blood samples. 
6.2.2. Materials and Methods 
6.2.2.1. Reagents and Chemicals 
Remifentanil (GI87084) and its main metabolite (GI90291A), an acid derivative, 
were obtained from Glaxo Smith Kline (Geneva, Switzerland). 6-Acetylcodeine was 
obtained from Lipomed (Arlesheim, Switzerland). All the other reagents and 
solvents in HPLC grade were purchased from Merck (Darmstadt, Germany). Solid-
phase extractions were carried out on Oasis HLB cartridges (Waters, Rupperswil, 
Switzerland). Deionised water was prepared on a MilliQ laboratory purification 
system. 
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6.2.2.2. Apparatus and Instrumental Conditions 
The LC-MS-MS apparatus was a LCQ Advantage from Thermo Finnigan (Allschwil, 
Switzerland) equipped with an ESI device operating in the positive detection mode. 
Chromatography was performed on a Symmetry C8 column (2.1 x 150 mm, 5 µm) 
from Waters (Rupperswil, Switzerland). The mobile phase was delivered at a flow 
rate of 200 µL/min. Each chromatographic run was performed with a binary, linear 
A/B gradient (solvent A 0.1% formic acid, solvent B acetonitrile). Elution began 
with the mobile phase at 12% B and 88% A for 1 min, then a linear gradient to 
percentage of 80% B over 6 minutes. The percentage of B was decreased back to 
12% for 3 minutes. For quantification, the selected ion monitoring mode was used to 
obtain the desired sensitivity. Table XIII lists the precursor and product ions and 
relative collision energy for each analyte. The heated capillary temperature was 
350°C, capillary voltage 3.8 kV, sheath gas (nitrogen) flow was 60 units. 
 
 Table XIII. Precursor and Main Product Ions and Relative Collision 
Energies of Remifentanil, its Metabolite and IS. 
 Compounds Precursor 
ion 
(m/z) 
Full scan 
MS-MS 
(amu) 
Main product ions 
used for 
quantification (m/z) 
Collision 
energy 
(%) 
 remifentanil 377.2 250-385 285.3, 317.1, 344.9 35 
 Main 
metabolite 
363.1 200-400 259.3, 302.8, 330.8 35 
 6-acetyl-
codeine 
342.1 200-400 225.0, 282.0 35 
 
6.2.2.3. Standard Preparation 
Stock solutions (1 mg/mL) of remifentanil and its metabolite were prepared in 
acetonitrile containing 0.1% formic acid. The stock solutions were diluted further 
with 0.1% formic acid. Calibration standards were prepared at different 
concentrations in the range of 0.5 to 10 ng/mL. Appropriate amounts of diluted 
solutions of remifentanil and its metabolite were added to tubes containing 1 mL 
heparinised whole blood and 20 µL of 50% w/w citric acid. 6-Acetylcodeine was 
prepared as internal standard (IS) at a concentration of 100 ng/mL. 
6.2.2.4. Extraction Procedure 
After blood sample collection it is imperative that enzymatic degradation of 
remifentanil is stopped immediately. 20 µL of 50% w/w citric acid were added to 1 
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mL heparinised whole blood to prevent hydrolysis of remifentanil via pH control and 
were freezed until the day of analysis. 100 µL of internal standard solution were 
pipetted to each sample. To precipitate proteins the samples were first vortexed with 
1 mL of methanol, then with 1 mL 0.174 M ZnSO4-solution and finally with 2 mL 
0.035M ZnSO4-solution. Then the samples were shaken for 20 minutes. The mixture 
was then centrifuged for 10 min at 4'500 rpm. The supernatants were diluted with 
water to 10 mL. 
 
The Oasis HLB extraction cartridges were conditioned with 1 mL methanol, and 
with 1 mL water. 9.9 mL of the solution was loaded on the cartridge. The sorbent 
was washed with 1 mL water, and eluted with 1 mL methanol. A new cartridge was 
used for each sample. Eluents were evaporated to dryness under a stream of dry 
nitrogen. The extracts were reconstituted in 100 µL acetonitrile/0.1% formic acid 
(10:90, v/v) and aliquots were injected into the HPLC columns. 
6.2.3. Results and Discussion 
The retention times of the compounds of interest were 5.2 min for 6-Acetylcodeine, 
5.4 min for remifentanil and 5.5 min for the metabolite of remifentanil (Fig. 15). Table 
XIV shows the coefficients of variation (CV) for the intraday and the interday 
precision of remifentanil and its metabolite. 
On eight different days 2 samples were quantified of each concentration. The CVs for 
the intraday precision were always less than 15% for remifentanil and its metabolite. 
CVs for remifentanil for the interday precision were 18.0%, 10.2% and 9.7% at 0.5, 2 
and 10 ng/mL, respectively. For the metabolite of remifentanil they were equal to 
15.0%, 11.9%, 8.9% for the same concentrations and respectively. 
 
Table XIV. Validation Data for Remifentanil and its Metabolite. 
 Concentration 
(ng/mL) 
CV % of Remifentanil CV % of the Metabolite of 
Remifentanil 
 
 Intraday Interday Intraday Interday 
 0.5 12.6 18.0 14.3 15.0 
 2 9.1 10.2 9.1 11.9 
 10 8.8 9.7 11.2 8.9 
 
The absolute recoveries of remifentanil and its metabolite in whole blood were 
determined by quantitating the amount recovered against standards made up directly in 
acetonitrile/water. 
Appendix 
91 
The overall remifentanil recovery was 78% and 76% for the metabolite of 
remifentanil. The procedure showed good linearity between the concentrations of 0.5 
to 10 ng/mL. 
 
 
Fig. 15. Representive chromatogram of an extracted whole blood sample of a test 
person at 1.96 ng/mL remifentanil, 6.38 ng/mL metabolite of remifentanil and IS.  
 
Fig. 16 and 17 show the whole blood concentration-time curves of remifentanil and its 
metabolite, respectively, after intravenous administration. With an automated system 
remifentanil was individually administered to the subjects according to a fix scheme. 
metabolite of 
remifentanil remifentanil 
IS 
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Fig. 16. Whole blood concentration-time curves of remifentanil after intravenous 
administration of remifentanil to 9 individuals (P01-P09). From 45 to 105 minutes the 
remifentanil whole blood concentration was expected to be at 1 ng/mL, from 120 to 
180 minutes at 2 ng/mL and from 195 to 255 minutes at 3 ng/mL. Blood samples were 
taken after 45, 105, 120, 180. 195 and 255 minutes. 
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Fig. 17. Whole blood concentration-time curves of the main metabolite of remifentanil 
after intravenous administration of remifentanil to 9 individuals. 
 
From 45 to 105 minutes the whole blood concentration was expected to be at 1 ng/mL, 
from 120 to 180 minutes at 2 ng/mL, finally from 195 to 255 minutes at 3 ng/mL. At 
different time points whole blood samples were taken and analyzed. 
 
Expected whole blood concentrations after remifentanil infusion were compared to 
real whole blood concentrations. The measured whole blood concentrations were all 
much deeper than the aimed whole blood concentrations (Table XV). The difference 
between the expected and the measured whole blood concentration were up to –54%. 
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 Table XV. Average of Remifentanil Whole Blood Concentrations of Nine 
Individuals after Infusion. Difference between the Expected and the Measured 
Whole Blood Concentration. 
 Measured whole 
blood concentration 
ng/mL 
 
Time 
(min) 
Expected whole 
blood concentration 
ng/mL 
Mean S.D. 
Difference (%) between 
measured and expected 
concentration 
 45 1 0.81 0.14 -19% 
 105 1 0.79 0.11 -21% 
 120 2 1.39 0.44 -31% 
 180 2 1.28 0.27 -36% 
 195 3 2.07 0.43 -47% 
 255 3 1.92 0.35 -54% 
 
A sensitive and specific assay for the determination of remifentanil and its metabolite 
in human whole blood using LC-MS-MS has been developed. The method has a 
validated range for remifentanil and its metabolite from 0.5 to 10 ng/mL and has been 
used to analyse clinical blood samples in a GLP certified study. 
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6.3. APOMORPHINE 
6.3.1. Introduction 
Apomorphine is indicated for the treatment of erectile dysfunction. LC-MS methods 
have not yet been published for the assessment of apomorphine in plasma. For use in a 
clinical study, a fast and sensitive assay method was developed to determine 
apomorphine in human plasma samples. 
6.3.2. Materials and Methods 
6.3.2.1. Reagents and Chemicals 
Apomorphine and 6-acetylcodeine was obtained from Lipomed (Arlesheim, 
Switzerland). All the other reagents and solvents in HPLC grade were purchased 
from Merck (Darmstadt, Germany). C18 EC cartridges were purchased from Spark 
Holland (Emmen, Netherlands). Deionised water was prepared on a MilliQ 
laboratory purification system. 
6.3.2.2. Apparatus and Instrumental Conditions 
The LC-MS-MS apparatus was a LCQ Advantage MAX from Thermo Finnigan 
(Allschwil, Switzerland) equipped with an ESI device operating in the positive 
detection mode. Chromatography was performed on a Phenomenex Synergi MAX-
RP column (2.0 x 75 mm, 4 µm) from Brechbuehler (Schlieren, Switzerland). The 
mobile phase was delivered at a flow rate of 500 µL/min. 
Each chromatographic run was performed with a binary, linear A/B gradient (solvent 
A 0.1% formic acid, solvent B acetonitrile with 0.1% acetonitrile). Elution began 
with the mobile phase at 5% B and 95% A for 1.5 min, then a linear gradient to 
percentage of 90% B over 3.5 minutes. The percentage of B was held for 2.2 min 
decreased back to 5% for 3.8 minutes. 
For quantification, the selected ion monitoring mode was used to obtain the desired 
sensitivity. Table XVI lists the precursor and product ions and the normalized 
relative collision energy for each analyte. The heated capillary temperature was 
350°C, ionization voltage 4.5 kV, sheath gas (nitrogen) and auxiliary gas flow were 
80 and 15 relative units, respectively. 
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 Table XVI. Precursor and Main Product Ions and Relative Collision 
Energies of Apomorphine and IS. 
 Compounds Precursor ion 
(m/z) 
Main product ions 
used for quantification 
(m/z) 
Normalized 
collision energy 
(%) 
 apomorphine 268.3 
 
218.7, 236.7, 237.7 35 
 6-acetylcodeine 342.1 225.0, 282.0, 342.0, 
343.0 
35 
 
6.3.2.3. Sample Preparation 
Stock solutions (0.1 mg/mL) of apomorphine were prepared in methanol. The stock 
solutions were diluted further deionised water. Calibration standards were prepared 
at different concentrations in the range of 1 to 30 ng/mL. Appropriate amounts of 
diluted solutions of apomorphine were added to plasma. 6-Acetylcodeine was 
prepared as internal standard (IS) at a concentration of 2000 ng/mL. 
6.3.2.4. Extraction Procedure 
100 µL of internal standard solution were pipetted to 1 ml of plasma of each sample. 
On-line SPE and elution was performed using the Prospekt 2 system. The C18 EC 
cartridge was conditioned with 1 mL methanol (5 mL/min) and with 1 mL water (5 
mL/min). 100 µL of the plasma mixture was loaded on the cartridge. The sorbent 
was washed with 1 mL water (2 mL/min), and eluted with the mobile phase during 
10 minutes. 
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6.3.3. Results and Discussion 
Representive chromatograms of a standard sample are shown at 1 ng/ml. The retention 
times of the compounds of interest were 3.7 min for apomorphine, and 3.9 min for the 
IS (6-acetylcodeine) (Fig. 18). 
 
 
Fig. 18. Representive chromatogram of a standard serum sample at 1 ng/mL 
apomorphine (left) and IS (right). 
 
Table XVII shows the coefficients of variation (CV) for the intraday and the interday 
precision of apomorphine. On six different days 2 samples were quantified of each 
concentration. 
 
 Table XVII. Validation Data for Apomorphine. 
 
 Concentration (ng/mL) CV % of apomorphine 
 
  Intraday Interday  
 2 11.6 11.4 
 10 6.8 8.8 
 20 4.5 7.4 
 
The CVs for the intraday and interday precision were always less than 15% for 
apomorphine. CVs for apomorphine for the interday precision were 11.6%, 6.8% and 
4.5% for the interday precision 11.4%, 8.8%, 7.4% at 2, 10 and 20 ng/mL, 
respectively. 
The procedure showed good linearity between the concentrations of 0.5 to 30 ng/mL 
with a correlation coefficient of 0.991 (Fig. 19). 
 
Apomorphine IS  
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Fig. 19. Validation data for apomorphine. 
 
Two different formulations of tablets with apomorphine were ingested. At different 
time points plasma samples were taken and analyzed (30 min, 15 min, 5 min before, 
and 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min and 360 min 
after ingestion of a tablet). Fig. 20 shows the plasma concentration-time curves of 
apomorphine. 
 
In determining bioequivalence, pharmacokinetic studies were conducted on each of 
the preparations in volunteer subjects. The bioequivalence of a formulation of a 
generic apomorphine compared to the reference product (Uprima®) was assessed in a 
study. 
 
Preparations are bioequivalent if the 90% confidence intervals (90% CI) between the 
two preparations, of cmax and AUC lie in the range 0.80-1.25. tmax was considered 
because the onset time is therapeutically relevant. 
 
Plasma samples were obtained at regular intervals and assayed for drug concentration.  
This data was used to assess key pharmacokinetic parameters such as area under the 
curve (AUC), peak concentration (cmax) and time to peak concentration (tmax). 
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Fig. 20. The plasma concentration-time curves of apomorphine are shown in two 
different formulations after tablet administration. The concentration of the Uprima® 
formulation is displayed in blue colour, the generic formulation in green. At different 
time points plasma samples were taken and analyzed. 
Test person A 
Test person B 
Test person C 
Test person D 
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 Table XVIII. Half-life and cmax of Apomorphine of 4 Different Test Persons in 
the Original Product and a Generic Formulations. 
 Proband t1/2 of apomorphine  
(min) 
cmax of apomorphine  
(ng/mL) 
  Uprima® Generic 
formulation 
Uprima® Generic 
formulation  
 P01 100 124 4.1 4.6 
 P02 95 107 8.5 6.5 
 P03 94 144 7.1 5.4 
 P04 107 89 8.4 10.4 
 mean 99 116 7.0 6.7 
 CV 6 24 2.1 2.6 
 
Table XVIII and XIX show the half-life, cmax, tmax and AUC of apomorphine in 4 
different probands in the original product (Uprima®) and in the generic formulation. 
Most of the parameters were similar between the 4 test persons. The mean of the AUC 
of the generic formulation was within the range of 0.80-1.25 compared to the mean of 
the AUC of the original product. The other pharmokinetic parameters (t1/2, cmax, tmax) 
of apomorphine didn’t differ significantly by the administration of the generic 
formulation. t1/2 was 99 and 116 minutes, cmax was 7.0 and 6.7 ng/mL, tmax was 79 and 
45 minutes for the original and the generic formulation, respectively. 
 
Table XIX. tmax and AUC of Apomorphine of 4 Different Test Persons in the 
Original Product and a Generic Formulations. 
proband tmax of apomorphine  
(min) 
AUC  
(h*mg/L*10-3) 
 Uprima® 
 
Generic 
formulation 
Uprima® Generic 
formulation 
P01 30 45 13.4 15.5 
P02 45 15 18.2 13.8 
P03 120 30 20.3 19.4 
P04 120 90 25.6 25.3 
mean 79 45 19.4 18.5 
CV 48 32 5.1 5.1 
 
Further studies have to be performed. 4 different test persons are not sufficient to 
prove bioequivalence. Usually, 18 to 24 subjects are required to perform a 
bioequivalence study for generic drug development. 
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